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2. ABBREVIATIONS  
 
ADAM a disintegrin and metalloproteinase 
ADAMTS a disintegrin and metalloproteinase with thrombospondin motifs 
ATP  adenosine triphosphate 
ATPase ATP synthase 
BCIP  bromochloroindolyl phosphate 
BSA  bovine serum albumin 
CD  cluster of differentiation 
cDNA  complementary deoxyribonucleic acid 
ctrl  control 
CTx   C-terminal cross-linked telopeptide of type I collagen  
DAB   diaminobenzidine 
DAPI   diamidino-2-phenylindole 
DIG   digoxigenin 
DMARD disease-modifying antirheumatic drug 
DNase  deoxyribonuclease 
dNTP  deoxyribonucleotide triphosphate 
ECM   extracellular matrix 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
FBS  fetal bovine serum 
FSD   functional secretory domain 
GM-CSF  granulocyte macrophage-colony stimulating factor 
GFP  green fluorescent protein 
GST  glutathione-S-transferase 
HLA  human leukocyte antigen  
ICTP   carboxyterminal cross-linked telopeptide of type I collagen 
IFN  interferon 
Ig  immunoglobulin 
IL   interleukin 
kD  kilodalton 
LB  Luria-Bertani 
M-CSF  macrophage-colony stimulating factor 
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MHC   major histocompatibility complex  
MMP  matrix metalloproteinase 
mRNA  messenger ribonucleic acid  
MT-MMP membrane-type matrix metalloproteinase 
NA  numerical aperture 
NBT  nitroblue tetrazolium 
NF-kappa B nuclear factor kappa B 
OA  osteoarthritis 
OPG  osteoprotegerin 
PBGD  porphobilinogen deaminase 
PT  pannus tissue 
RA  rheumatoid arthritis 
RANKL  receptor activator of nuclear factor kappa B ligand 
rh  recombinant human 
RNase  ribonuclease 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siRNA  small interfering ribonucleic acid 
ST  synovial tissue   
TGF  transforming growth factor  
Th  helper T cell 
TNF   tumour necrosis factor 
TIMP  tissue inhibitor of metalloproteinases 
TRAF   tumor necrosis factor receptor-associated factors  
TRAP   tartrate resistant acid phosphatase 
UTP  uridine triphosphate 
qRT-PCR quantitative reverse transcriptase-polymerase chain reaction 
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3. ABSTRACT  
 
Rheumatoid arthritis (RA) is a chronic inflammatory syndrome that causes polyarticular 
swelling, stiffness, pain and potential for structural damage of joints and functional disability. 
One of the characteristic features of RA is a symmetrical pattern of the joint involvement 
affecting usually multiple small diarthrodial joints of the hands and feet. Despite of intensive 
research, the aetiology of the disease has remained unclear. It is assumed that an unknown 
antigen reaches the synovial tissue, initiating a local immune response leading to synovitis. 
Continuous inflammation leads to synovial hyperplasia and pannus formation, which is a soft 
tissue expanding on cartilage and invading into it and the underlying bone matrix. The 
leading edge of pannus is composed of fibroblast- and macrophage-like cells, which produce 
proteinases able to cause destruction of articular cartilage. Co-operation of mesenchymal 
cells and macrophage-like progenitor cells leads to local formation of osteoclasts, which 
invade the subchondral bone using acid attack and acidic proteinases. Pannus invasion leads 
to bony erosions, which are more or less permanent signs of joint damage.   
 
Proteolytic pathways play major roles in the development of tissue lesions in RA. The 
degradation of extracellular matrix proteins is an essential consequence of pannus formation 
and invasion. Hyaline articular cartilage, which covers the articulating ends of bones, is 
mainly composed of collagen II and proteoglycan, and lies on a subchondral bone plate 
mostly composed of collagen I, which all are substrates for several metalloproteinases and 
cathepsins. In RA, these proteinases are involved in the degradation of articular cartilage and 
demineralized subchondral bone.  
 
The aim of the study was to analyze the mechanism of pannus expansion and invasion into 
cartilage and subchondral bone, especially involvement of pannus derived proteinases and 
factors involved in matrix degradation and osteoclastogenesis. The key molecules concerned 
in these processes were studied at protein and mRNA levels using immunohistochemical 
staining, Western blotting, ELISA, in situ hybridisation and quantitative RT-PCR in 
rheumatoid patient and osteoarthritic control patient samples, as also in cytokine-stimulated 
and non-stimulated fibroblast and monocyte cell cultures. Formation of multinuclear 
osteoclast-like cells from peripheral blood mononuclear cells and mouse 
monocyte/macrophages was studied and a potential fusion protein was over-expressed using 
gene transfer (transfection) or inhibited using gene silencing (short interfering RNA 
 Abstract  
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technology). The role of one of the most interesting bone degradative enzymes, cathepsin K, 
was studied more closely by using a pycnodysostosis arthritis patient as a human cathepsin K 
“knock-out” arthritis model.   
 
Matrix metalloproteinases (MMPs) form a large “neutral” proteolytic enzyme family, which 
upon release from intracellular to the extracellular space are therefore able to degrade 
extracellular matrix. We observed significant expression of MMP-3 in pannus tissue, 
especially when stimulated by IL-1β. It could be one of the key enzymes in RA and is likely 
to contribute to joint destruction by directly degrading cartilage. In contrast, TNF-α 
stimulated MMP-1 was hypothesized to be involved in pannus invasion in early RA, both in 
inflammation and in degradation of extracellular matrix. Both these MMPs activate other pro-
proteinases in complex cascades leading to joint destruction. Interestingly, MMP-13 was not 
found in traumatic synovium tissue samples, but was expressed in RA. However the 
increased expression was more prominent in osteoarthritis than RA samples.    
 
Bone resorption requires demineralization of bone matrix by osteoclast-derived hydrochlorid 
acid as the first step. Osteoclasts have naturally been implicated in bone destruction in RA 
and we showed that pannus fibroblasts express a receptor activator of nuclear factor kappa B 
ligand (RANKL) able to stimulate osteoclast differentiation in the bone-pannus junction. The 
relation between RANKL and its natural inhibitor, a decoy receptor osteoprotegerin (OPG), 
in pannus tissue is imbalanced in favour for osteoclastogenesis. Some proteins of a 
disintegrin and a metalloproteinase (ADAM) family have been implicated in cell fusion. A 
recombinant protein of ADAM8 has been shown to be capable to induce osteoclast-like 
multinuclear cell formation and activity, perhaps by fusion of mononuclear precursor cells 
via interactions mediated by its disintegrin and/or cysteine-rich domain. We found an 
increased expression of ADAM8 in the pannus-hard tissue junction. Cathepsin K, a 
lysosomal acidic cysteine endoproteinase, is secreted outside the cell, especially into acidic 
environment between osteoclast and bone, where it degrades demineralized bone collagen 
matrix. However, absence of this important enzyme did not prevent bone degradation as was 
shown in our pycnodysostosis patient, who also had erosive arthritis, indicating that other 
enzymes can take over the role of cathepsin K. 
 
In this study we explored pannus tissue in RA and its capability to invade into rheumatoid 
cartilage and bone by stimulating degradative enzymes or proteins, which can stimulate the 
 Abstract  
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formation of multinuclear osteoclasts by cell fusion. The capability of nature to bypass 
proteins and factors by replacing them with similar ones will be a clinical problem, when 
medication is turning towards more specific biological drugs. A better understanding of 
pannus tissue invasion into cartilage and subchondral bone may provide an opportunity to 
find specific targets to treat this destructive disease, which could be useful in prevention and 
treatment to slow down or inhibit the degradation of joint structures and impairment of joint 
function. 
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4. REVIEW OF THE LITERATURE 
 
4.1 RA and joint destruction 
 
4.1.1 Structure of the joint 
 
The diarthroidal synovial joint is a mixture of highly specialized connective tissues of bone, 
hyaline cartilage, synovial tissue, ligaments, menisci, tendons and fibrous capsule. Although 
the cells responsible for the synthesis of tissues are derived from the same mesenchymal 
precursor cell line, the extracellular matrix in all connective tissues is different and depends 
on the cells and their function in these tissues. In diseases such as rheumatoid arthritis (RA) 
and osteoarthritis (OA) degradation of the tissue exceeds its synthesis, resulting in a net 
decrease in the amount of extracellular matrix finally leading to erosions and thinning of the 




Skeleton is an organ system, which consists of mineralized osseous tissue, also called bone 
tissue, endosteum, periosteum, bone marrow, nerves, blood vessels, lymphatic vessels and 
cartilage. Bone is composed approximately to 70 % of inorganic, mainly mineral compound 
called hydroxyapatite, to 22 % of organic material, mainly collagen type I and to 8 % water. 
Morphologically there are two types of bone: porous trabecular bone, also known as spongy 
bone, and dense cortical bone, also known as compact bone. 
 
The maintenance of normal bone mass depends on the balance between osteoclastic bone 
degradation and osteoblastic bone formation following it. Osteoclasts are formed by fusion 
from the monocyte/macrophage precursor cells into multinucleated giant cells, which express 
osteoclastic markers cathepsin K, tartrate-resistant acid phosphatase (TRAP) and calcitonin 
receptor (Sapp 1976, Baron et al. 1986, Schett 2007) (Figure 1) and able to resorb bone. 
Formation of osteoclasts requires the presence of macrophage colony-stimulating factor for 
macrophage precursors (M-CSF; Tanaka et al. 1993) and RANKL as the differentiation 
factor to promote fusion (Wong et al. 1997, Anderson et al. 1997, Yasuda et al. 1998). For 
some information of the adjunctive role of tumor necrosis factor-α (TNF-α) and interleukin-
1beta (IL-1β), see 4.1.4. on cytokines below. RANKL is produced by synovial fibroblast, 
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bone marrow stromal cells, lymphocytes, vascular smooth muscle cells and mast cells. Both 
M-CSF and RANKL mediated interactions are necessary for osteoclastogenesis, because a 
lack of either one of these molecules is sufficient to block osteoclast formation. M-CSF acts 
through colony stimulating factor 1 receptor (c-fms) on the precursor cells and RANKL, a 
member of the TNF superfamily, acts through RANKL receptor RANK (Dougall et al. 1999). 
The regulation of osteoclast differentiation is also affected by osteoprotegerin (OPG), a 
RANK homolog or decoy receptor, which blocks the RANKL-RANK interaction (Simonet et 
al. 1997). OPG is a member of TNF receptor superfamily and expressed by synovial 
fibroblasts, osteoblasts and endothelial cells.  Osteoclasts are found only close to mineralized 
tissue, the presence of which might operate as an additional local signal for final osteoclast 
differentiation. When activated, osteoclasts move to areas of microfractures in the bone by 
chemotaxis. Bone resorption starts when migrating osteoclasts adhere to the bone matrix, 
which leads to cytoskeletal reorganization and cell polarization (Väänänen et al. 2000).  
 
 
Figure 1. Bone resorption by osteoclast occurs in two phases, first bone matrix is 
demineralized by local acidic environment and secondly, the collagen I-rich matrix is 
degraded by lysosomal secreted cathepsin K and other such acidic proteinases. 
 
Polarization creates four morphologically distinct areas of plasma membrane: i) the 
basolateral membrane, not connected to the bone matrix, ii) the tight sealing zone, where F-
actin ring is in close indirect contact with the bone surface, iii) the ruffled border, a 
membrane area surrounded by sealing membrane facing the resorbing surface and iiii) a 
functional secretory domain (FSD) on the opposite site of the bone, a target for transcytotic 
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vesicles containing resorbed pieces of bone (Salo et al. 1996). After morphological 
differentiation to polarized cells, osteoclasts secrete protons by proton pump ATPase into the 
sealed extracellular compartment, the resorption lacunae, also called Howship’s lacunae, to 
form an acidic environment, pH 3 or less (Baron et al. 1985, Silver et al. 1988 , Blair et al. 
1989) for the dissolution of the bone minerals. This is followed by secretion of proteolytic 
enzymes for the degradation of exposed non-mineralized collagen matrix. The degraded bone 
matrix is either processed extracellularly or taken into the osteoclasts by endocytosis, 
followed by degradation within lysosomes (Salo et al. 1997). In addition to bone forming and 
resorbing cells, osteocytes are found embedded in the bone matrix located in their 
intercellular and -connected lacunar network and flattened bone lining cells on bone surfaces. 
Both of these cells are formed from mature osteoblasts. During development of RA, 
osteoclasts are formed locally from mononuclear precursor cells in the inflamed joint tissue 




Articular cartilage, also due to its somewhat glass-like visual appearance called hyaline 
cartilage, is found in diarthroidal joints covering articulating bone surfaces and absorbs the 
biomechanical impact and shear load upon movements of the gliding surfaces against 
another. Cartilage distributes the load and thus protects the subchondral bone from high 
stresses and reduces contact pressure. Cartilage provides a smooth, well lubricated surface for 
low-friction movement between joints. Cartilage structure is multilayered and identification 
of each layer is based on different characteristics like cell shape, morphology, cellular 
organization, collagen orientation and pericellular matrix deposition (Tyyni and Karlsson 
2000) (Figure 2A). Cartilage is composed of water (70-80 %) and of solid phase, primarily of 
type II collagen (10-15 %), aggrecan (5-10 %) and various collagen decorating leucin-rich 
repeat protein molecules. Aggrecans are large proteoglycans, which fill the gaps of the 
collagen network by forming large aggregates interacting with hyaluronan and link proteins, 
and are highly hydrated. They provide the cartilage with a considerable swelling pressure and 
explain its ability to resist sudden compressive impact loads while water is seeping out from 
and later back to the matrix. Cartilage consists of lesser extent of collagen type IX and type 
XI and a relatively small number of chondrocytes, which are the main cells found in 
cartilage. Chondrocytes are located in lacunae and their function is to produce and maintain 
the cartilaginous matrix. Cartilage also contains a few mesenchymal stromal cells in the 
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superficial zone of the cartilage (Dowthwaite et al. 2004, van Osch et al. 2009). Collagen 
fibrils resist the swelling pressure of the proteoglycan matrix and give cartilage its tensile and 
shear strength. Alignment of collagen fibers give each zone particular biomechanical 
advantages which are provided by the arcade-like structure of the fibers: tangential, 





Figure 2. The structure of articular cartilage. A) On the left side an illustration of the zonal 
architecture of articular cartilage. Superficial zone cells are small, elongated in shape, 
parallel to the joint surface; the middle zone cells are rounded and do not exhibit an 
organized orientation relative to the surface. Deep zone cells form groups of three or more 
cells arranged in columns perpendicular to the surface. On the right is a representative 
histological image with Safranin O staining from bovine articular cartilage of a knee joint. 
B) Schematic diagram of the cartilage matrix illustrating the arcade structure of the collagen 
fibres, starting off the subchondral bone and bending over as they approach the articular 
surface. 
 
of cartilage is the lack of blood vessels, lymphatics and nerves, which exposes it to externally 
controlled motor programs and the highly vascularized synovial tissue, which produces 
synovial fluid and provides thus nutrition for cartilage. In addtion, subchondral bone, which 
is a vascularized structure, also provides nutrients directly from the circulation to the deep 
zones of the cartilage. In RA, this articular hypoxic environment is changed due to 
neovascularization or angiogenesis, one of the characteristic features of this disease, which 
allows infiltration of inflammatory cells. The primary cause of cartilage degradation has been 
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suggested to be increased expression, strategic localization and enhanced activity of various 
proteolytic enzymes. In RA, degradation of cartilage is mediated by proteinases, derived from 
the inflamed synovium, activated synovial fluid granulocytes and stimulated chondrocytes. 
The loss of aggrecan is considered as an initial step during cartilage degradation, which is 
then followed by weakening of the collagen fibre network, followed by enzymatic and 
biomechanical degradation of collagen fibrils. In RA, degradation of unmineralized cartilage 
is suggested to be mediated, not by multinuclear osteoclasts or chondroclasts, but primarily 
by the synovial pannus tissue (Bromley and Woolley 1984). Furthermore, the close physical 
relationship between fibroblast-like and macrophage-like cells in the pannus also suggest that 
it has a potential to locally produce osteoclasts, which via hydrochlorid acid and cathepsin K 
mediate demineralization and collagen matrix degradation of articular bone. 
 
4.1.2 Description of RA 
 
The first recognized description of rheumatoid arthritis dates back to 1800 and was made by 
Augustin Jacob Landré-Beauvais in his thesis for his medical doctorate. RA is the most 
common inflammatory arthritis and despite of intense research, the etiology of the disease 
remains unclear, but it is interesting that compared to e.g. OA and ankylosing spondylitis, RA 
may be a relatively new disease. RA is associated with significant morbidity and increased 
mortality, and the prevalence rate of RA in different populations is 0.5-1 %, affecting women 
two to three times more often than men. Onset is uncommon in young people, the incidence 
rises with age and in Finland the mean age is approximately 59 years (Kaipiainen-Seppänen 
and Aho 2000). In Finland, the prevalence of RA is 0.8 %, approximately 32 000 suffer from 
this disease and 2000 adults get affected per year (Hakala and Kauppi 2007). The American 
College of Rheumatology 1987 revised criteria for the classification of RA are listed in table 
1 and require at least 4 criteria to be present for at least 6 weeks (Arnett et al. 1988). RA is a 
heterogeneous syndrome, because it is defined by the presence of 4 or more criteria out of 7.  
 
RA is not an inheritable disease, but close relationship raises the prevalence up to 2-4 % in 
first-degree relatives and dizygotic twins and up to 12-15 % in monozygotic twins (Lee and 
Weinblatt 2001). There is an inadequate knowledge of risk factors, but one of the most 
important predisposing environmental factors is smoking. Hormones or X chromosome-
linked gene dose effects may affect the prevalence, which could explain the higher risk of RA 
in women. Increased disease activity after pregnancy, or termination of pregnancy, points to 
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the same direction. RA has also been suggested to be associated with joint injury and other 
environmental stimuli, like viruses, bacteria and stress, but this is uncertain. In contrast, 
certain major histocompatibility complex (MHC) class II genes and some other genes and 
regions are associated with RA and/or its severity. In conclusion, both genes and environment 
may contribute to the development of RA. 
 
 
Table 1.  Classification criteria for rheumatoid arthritis as defined by The American College 
of Rheumatology in 1987. 
 
The American College of Rheumatology 1987 revised criteria 
1) morning stiffness lasting at least 1 hour  
2) joint swelling at least in three different areas  
3) joint swelling in hand 
4) symmetric joint swelling in the same area 
5) rheumatoid nodules 
6) rheumatoid factor in the blood 
7) radiographic erosions and/or periarticular osteopenia  
 
 
RA is considered as a chronic autoimmune disease, which causes the immune system to 
attack against substances or tissues normally present in the body. There is no specific 
diagnostic test available for RA. Different potential autoantigens are found in RA like 
circulating serum proteins, citrullinated proteins and peptides, nuclear components and 
components of articular cartilage. Rheumatoid factor, an autoantibody against the Fc portion 
of IgG, has traditionally been used in the diagnosis, but only 70 to 80% of RA patients have 
this factor in their serum and otherwise also normal healthy individuals can have it. 
Antibodies against citrullinated peptides have been shown to be more specific than 
rheumatoid factor. Recently antibodies directed against citrullinated collagen type I and type 
II have been detected more often in RA patients than in control groups. RA affects primarily 
joints, but it also affects other organs and is considered a systemic disease. The reason for the 
preferential and symmetric involvement of the small joints is not known though neurogenic 
inflammation in densily innervated small joints of the hands and feet has been suggested to 
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play a role here (Konttinen et al. 1994, Kidd et al. 1989). Trauma might have some localizing 
effect, so called deep Köbner’s phenomenon, for example, rheumatoid nodules typically arise 
in places of the body subjected to pressure, e.g. on the extensor side of the ulnar bones. RA 
affects multiple synovial joints in a symmetrical fashion, being thus a polyarthritis with 
midline symmetry suggesting that cross-spinal reflexes rather than circulating cytokines play 
a role in the pattern of joint localization. Synchondrosis, synostosis or enthesis are rarely 
affected. ACR criteria refer to occurrence of synovitis in at least three different joint areas, 
although officially involvement of four joints would actually still be named oligoarthritis. As 
already mentioned, involvement of the small joints of the hands and feet is typical, although 
larger joints, like the shoulder and knee joints can be involved. The inflammatorily affected 
synovial tissue, which lines the non-cartilaginous surfaces of the interior joint lining, is 
vascular soft connective tissue with type I and III collagens as its key extracellular matrix 
(ECM) components. This tissue is organised so that vascularised sublining and fibrotic or 
adipose connective tissue stroma supports a lining or membrane comprised of two distinct 
cell types. Self renewing fibroblast-like type B synoviocytes (Konttinen et al. 1989) produce 
intercellular matrix molecules, cementing the lining cells together to a relatively coherent 
structure, and also secrete high molecular weight hyaluronan to increase the viscosity of the 
synovial fluid. Macrophage-like type A synoviocytes, the pregenitors of which are recruited 
from the circulation, clear the apoptotic neutrophils and other cells from the joint cavity 
(Müller-Ladner et al. 2005). The microcirculation of the synovial lining of joints is facilitated 
by a high density of fenestrated capillaries situated very close to the synovial surface and 
oriented toward the joint cavity. This orientation and intercellular wide gaps of the surface 
allow rapid exchange of fluid. Inflammatory mediators increase the permeability of the 
capillary cell walls by increasing the size of the pores, which increases leakage of fluid to 
inflammed tissue, contributing to swelling of the joint (Levic 1981). Bleeding may also occur 
from ruptured capillaries. Synovial fluid contains ultrafiltrated components of plasma, 
lubricin synthesized by superficial zone chondrocytes and synovial stromal cells and 
hyaluronic acid synthesized by synovial lining, which act as nutrients and lubricants for the 
joint cartilage. Type B lining cells contain lamellar bodies or phospholip scrolls (Dobbie et 
al. 1995), which are not seen in routine slides, because the fat solvents used in sample 
processing dissolve them way, but which may provide various phospholipis to promote 
contact point lubrication, perhaps with the help of surfactant proteins. The synovial lining is 
normally only a few cell layers thick, however, in RA there is an extensive increase in the 
number of cells in the lining layer, which becomes several layers thick and forms villi 
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because in particular the macrophage-like type A synoviocytes increase in numbers. 
Sublining layer becomes infiltrated with inflammatory mononuclear cells, including 
lymphocytes, macrophages and mast cells. Neutrophils increase somewhat in numbers in RA 
synovitis tissue, but they transmigrate rapidly from the intravascular compartment via the 
synovium to synovial fluid in the joint cavity, where they survive only 1-3 days, but due to 
their rapid turnover still form the major cell type in there. All these features contribute to the 
clinically typical joint swelling. All of these cells, including resident fibroblasts, produce 
cytokines, which together with locally produced autoantibodies, such as rheumatoid factor 
and anti citrullinated peptide antibodies, and immune complexes and complement, maintain 
the chronic inflammation in RA tissue. Also extraneous factors, like dietary intake of N-
glycolylneuraminic acid (Neu5Gc), particularly from red meat and milk products, have been 
associated with chronic inflammation. As a result of inflammation, hyaluronan is increasingly 
locally synthesized and partly depolymerised leading to morning stiffness (Saari et al. 1991), 
at the same time as molecules which sensitize the primary afferent nociceptive nerves lead to 
tenderness on movement and pressure, or even pain at rest (Konttinen et al. 1994). A short 
and self-limited activation of the immune system has no clinically significant effect on bone, 
whereas prolonged immune activation is the main contributor to juxta-articular, erosive and 
systemic bone loss, which together with the increased propensity to fall lead to increased 
fracture risk in patients with chronic inflammatory rheumatic disease (Caetano-Lopes et al. 
2009).  
 
Continuous inflammation in synovium leads the membrane expansion, which forms pannus 
(Gr. A cloth) with an avascular leading edge containing fibroblast-like and macrophage-like 
cells and vascular granulation tissue, which reach onto hyaline articular cartilage and 
subchondral bone degrading and invading them. This leads to the formation of the typical 
erosions (Kobayashi and Ziff 1975, Shiozawa and Ziff 1983, Shiozawa et al. 1983) (Figure 
3). Synovial expansion in RA is also referred as malignant mesenchymal transformation 
(Fassbender and Gay 1988) and a recent study confirms that the activation and destruction in 
RA uses similar pathways as are observed in progression of malignant diseases (Senolt et al. 
2006). Pannus can also degrade cartilage from other side by invading first to underlying bone 










Figure 3. A schematic presentation of a normal (left) and arthritic (right) joint. Pannus 
invasion into cartilage and subchondral bone is illustrated as synovial hyperplasia 
 
The leading edge of pannus is composed of a cell layer of fibroblast- and macrophage-like 
cells, which can produce proteinases, receptor activator of nuclear factor kappa B ligand 
(RANKL) and other factors causing directly or indirectly destruction of cartilage and bone 
matrices (Kinne et al. 2007, Muller-Ladner et al. 2007). During pannus invasion, the cartilage 
is covered with several layers of fibroblast-like cells, while invasion of macrophage-like cells 
occurs behind and beneath this layer (Shiozawa et al. 1983). Three types of pannus in 
cartilage-pannus junction have been observed: 1) cellular pannus without proliferating 
vessels, rich in phagocytic and fibroblastic cell, invaded in the hard tissues, 2) cellular pannus 
with proliferating small blood vessels, penetrated into the hard tissues, and 3) inactive fibrous 
pannus overlaying the hard tissues (Kobayashi and Ziff 1975). Two different histological 
features of cartilage-pannus junction have been observed, a distinct invasive cartilage-pannus 
junction, where a distinct junction is defined lying immediately adjacent to the cartilage 
surface; and a diffuse fibroblastic cartilage-pannus junction, also known as transitional 
fibroblastic zone, where the soft-hard tissue junction forms an indistinct cartilage-pannus 
junction (Allard et al. 1988). Eventually, synovitis leads to erosion of the joint surface, 
contributing to joint deformity, laxity and loss of function. 
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Medications to treat rheumatoid arthritis are used to relieve or reduce pain, reduce joint 
inflammations like swelling and tenderness, prevent or delay joint damage and deformity, 
improve daily function, prevent permanent disability and improve the quality of life. Apart 
from symptomatic non-selective and COX-2 selective non-steroidal anti-inflammatory drugs, 
medicines called disease-modifying antirheumatic drugs (DMARDs) decrease pain and 
inflammation, but also reduce or prevent joint damage. They are nowadays used early in the 
course of the disease and usually in changing evidence-based and empirical combinations 
with other such drugs. These immunomodulatory drugs are divided into two categories, non-
biological DMARDs (eg. methotrexate, oxichloroquine, leflunomide) and biological 
DMARDs (eg. infliximab, etanercept, adalimumab, anakinra), which work in several 
different ways to suppress the patient’s overactive immune and inflammatory systems (Lee 
and Weinblatt 2001, Feldmann and Maini 2008). The commencement of the DMARD effect 
may take over weeks or months (“slow-acting”), so nonsteroidal (eg. acetylsalicylic, 
ibuprofen) and steroidal (eg. glucocorticoids) anti-inflammatory drugs are used to provide 
faster relief of pain, stiffness, and swelling and maybe used also thereafter as adjunctive 
medication. Glucocorticoids have been traditionally classified as steroidal anti-inflammatory 
agents, but according to research data they also have slow acting, disease modifying action 
(Kirwan 1995, van Everdingen et al. 2002).  Non-biological DMARDs are combined with 
each other or with biological DMARDs. Bisphosphonates, such as zolendronic acid diminish 
bone degradation by inhibiting osteoclast activity and expression of tissue degrading 
proteinases (Valleala et al. 2003). Bisphosphonates do not suppress inflammation, but are 
used successfully in combination with anti-rheumatic therapy to slow down destruction of 
bone and to prevent glucocorticosteroid mediated osteoporosis. The medical and occupational 
prognosis of the patients is better if the DMARD therapy is started early and targeted to 
achieve remission (Möttönen et al. 1999, Puolakka et al. 2004). . 
 
4.1.3 Cell population in synovitis 
 
Various cell populations, including monocytes/macrophages, B cells, T cells, endothelial 
cells, mast cells and fibroblasts are involved in the pathogenesis of RA (Firestein 2003). Two 
dominant cellular processes supposed to be operating in rheumatoid joint destruction are 
synovial lining hyperplasia and lymphocyte dependent immune responses (Figure 4A-C). 
Synovial hyperplasia is characterised by proliferating synovial fibroblasts and recruitment of 
infiltrating macrophages. Pannus can be envisioned as an extension of the synovial lining 
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attaching to and growing along the cartilage surface and into the subchondral bone (Figure 
4D and E). Synovial fibroblasts originate from mesenchymal stem cells but are under normal 
homeostasis mainly maintained as a result of local proliferation. The role of type B synovial 
fibroblasts-like cells is to provide intercellular matrix molecules, such as type IV collagen 
(Poduval et al. 2007) and laminins (Konttinen et al. 1999a), to glue the lining cells to each 
other, and hyaluronan, lubricin and surfactant proteins for export for joint lubrication into 
joint cavity and adjacent cartilage. Type B synoviocytes are also involved in matrix 




Figure 4. A) Synovial lining hyperplasia in RA. B) Synovial lining in OA. C) Macrophage 
and lymphocyte infiltrates in RA. D) Pannus invasion into cartilage in RA. E) Pannus 
invasion into bone in RA. F) Multinuclear osteoclast (arrowhead) in the bone-pannus 
junction. Cell nuclei and proteins were stained using hematoxylin-eosin stain (A-E) and 
multinuclear osteoclast using TRAP stain (F). 
 
comprises changes in growth and expression, as well as responses to various stimuli. In early 
RA, synovial fibroblasts are probably activated already by innate immune system leading to 
production of inflammatory cytokines for attraction of inflammatory cells to the synovium 
and matrix destructive proteins for early perpetuation into surrounding tissues. In advanced 
RA, synovial fibroblasts are the main source of destructive molecules during pannus 
invasion, and the best known molecules involved in the destruction of the cartilage and bone 
are MMPs and cathepsins (Konttinen et al. 2000a, Rengel et al. 2007). 
 Review of the literature  
24 
 
Monocyte/macrophages, as also osteoclasts and dendritic cells involved in RA (Figure 4F), 
are originated from myeloid progenitor of hematopoetic stem cells. These cells are not only 
activated and increased in synovial membrane and pannus-hard tissue junction for local 
response, but are also activated in peripheral blood and subendothelial space to mediate 
systemic responses. The increased filtration of macrophages correlates with the radiological 
progression of joint destruction (Mulherin et al. 1996). In RA and in inflammation, 
macrophages are activated by soluble stimuli or by cell-cell contact to produce pro-
inflammatory effectors and tissue-degrading enzymes but also regulatory proteins, and 
participate both in the initiation and perpetuation of inflammation (Ma et al. 2003). 
 
Development of RA may require triggering of the innate and/or the adaptive immune 
systems. Microorganisms, like bacteria and virus, will encounter the innate immune system 
so that these microbes are recognized based on their conserved pathogen-associated 
molecular patterns. In the adaptive immune system, which needs several days to develop a 
strong immune response and immunological memory, the B-cells and T-cells are affected by 
antigen which guides antibody and cytokine production to promote antigen removal. T-cells 
are considered to be central orchestrating components of the immune-mediated pathology in 
RA, which are of relevance not only for the immune system, but also regulate inflammation 
and tissue destruction. RA is described as an autoimmune disease, in which the immune 
system recognizes self-structures or autoantigens. It has been suggested that these 
autoantigens could in part be cartilage matrix collagen type II or some other cartilage specific 
and immunologically priviledged structure, which upon solubilisation or partial degradation 
can associate with the major histocompatibility complex (MHC), especially HLA-DR1 and 
HLA-DR4, on antigen presenting cells (Li et al. 2002, Brand et al. 2003). During the 
development of RA degradation of cartilage matrix may instead of dominant epitopes 
generate so called cryptic epitopes, which is envisioned to promote autoimmune responses 
and also to maintain it (Lanzavecchia 1995). 
 
In RA, both the antibodies and the immune cells play a role in pathology. Disturbed immune 
T-cell homeostasis could contribute to joint pathology via impaired function of regulatory T 
cells and facilitation of pathogenic helper T-cells (Th cells). Studies of helper T cells 
originally led to the classification of RA as a Th1-like disease (Miossec and van den Berg 
1997). This cell population, predominantly producing interferon-gamma (IFN-γ) and 
interleukin-2 (IL-2), sometimes in combination with low levels of IL-4 and IL-10, was found 
 Review of the literature  
25 
 
to be dominant in RA synovium. In contrast, T cells predominantly producing IL-4 and IL-10 
with Th2 cell phenotype were rarely found. One of the main effects of this Th1/Th2 
imbalance is increased production of tumor necrosis factor-alpha (TNF-α), also a Th1-
associated cytokine, which activates a cascade leading to chronic inflammation and 
destruction of hard tissues as can also be deduced based on the beneficial therapeutic effect of 
TNF-inhibitors in the treatment of RA (Elliot et al. 1994). Recently a novel Th cell subset 
producing IL-17 but not IFN-γ or IL-4, has been found and named Th17. Th17 pathway is 
involved in inflammation and these cells in mice are capable to enhance osteoclastogenesis 




Cytokines are low molecular weight proteins, acting locally as intercellular mediators and are 
important regulators in major biological processes. Cytokines are produced in quite small 
quantities, but usually have extensive effects, acting not only in direct events, but also 
subsequently in secondary events. This high efficiency is due to the significant avidity of 
cell-bound receptors and the ligand-induced activation of numerous potent intracellular 
signalling cascades. In RA, disturbance of immune system leads to the production and release 
of inflammatory mediators into the synovium and synovial fluid by infiltrating cells and 
resident synovial cells. Cytokines are considered to take part in each step of the development 
of RA disease from early autoimmunity step through continuous chronic inflammation into 
destruction of joint tissue. Numerous cytokines are expressed in synovial tissue and 
imbalance between pro- and anti-inflammatory cytokines induces chronic inflammation 
(McInnes and Schett 2007).  
 
The inflamed synovium contain various macrophage- and fibroblast-derived cytokines that 
can support the activation of T-cells and vice versa. TNF-α and IL-1β, which have been 
widely studies in synovial tissue and in clinical studies, are considered as the main 
proinflammatory cytokines in the pathogenesis of RA (Feldmann et al. 1996, Maini et al. 
1999, Bresnihan 2001). These cytokines are produced by synovial monocyte/macrophages, 
fibroblasts, lymphocytes and osteoblasts. Both TNF-α and IL-1β induce inflammation in 
arthritic joints and are also in part responsible for pannus invasion and the subsequent damage 
of bone and cartilage. TNF-α and IL-1β have a dual role in osteoclastogenesis, first by 
inducing RANKL expression and secondary, like TNF-α, by binding directly to osteoclast 
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precursor cells, and like IL-1β by modulating the expression of RANK in these cells and thus 
promoting osteoclast formation. TNF-α can independently stimulate osteoclast formation in 
the absence of the RANKL-RANK interaction, but in the presence of M-CSF (Kobayashi et 
al. 2000). Differentiation is mediated via TNF receptor on osteoclast precursor cells. IL-1 can 
directly stimulate osteoclast activation throught IL-1 receptor (Jimi et al. 1999) and this 
interaction is required for osteoclast function in TNF-α-stimulated precursor cell 
differentiation. Furthermore, TNF-α appears to influence the distribution of osteoclast 
precursor cells in the body by increasing their influx from the bone marrow into synovium. 
These cytokines participate in final steps of the degradation process by stimulating the 
synthesis of matrix degrading enzymes. 
 
Cytokines are also modulating many animal models of arthritis. Inhibition of TNF-α 
suppresses various animal arthritis models, whereas the overexpression induces erosive 
inflammatory arthritis (Keffer et al. 1991). In animal models of arthritis, overexpression of 
IL-1 led to pannus formation and bone degradation (Ghivizzani et al. 1997), while blocking 
of IL-1 reduced disease activity and bone destruction (Joosten et al. 1999). Furthermore, 
therapeutic blockade of TNF-alpha suppresses clinical disease activity in 60-70% of patients 
with RA, while IL-1beta inhibition yields more moderate responses. On the other hand, both 
therapeutic approaches reduce or even prevent the extension of bone erosions (Maini and 
Taylor 2000).  
 
Lately, more attention has been paid to IL-17, because IL-17 producing Th cells were found 
in synovial tissue (Chabaud et al. 1999). IL-17 refers to a group of cytokines that shares only 
a little homology with other cytokines. Six family members have been identified to date, 
which bind to a unique class of cytokine receptors. IL-17 is involved in pro-inflammatory 
activity as they can induce secretion of IL-6, IL-8 and GM-CSF (Gaffen et al. 2004). IL-17 
can be also considered as a potent inducer of TNF-α, IL-1β and RANKL and, thus, does not 
only induce inflammation and cartilage degradation, but also osteoclastogenesis and bone 
resorption (Kotake et al. 1999, Jovanovic et al. 1998). IL-17 synergises with TNF, but also 
enhances inflammation and destruction independent of TNF-α and IL-1β (Koenders et al. 
2006). IL-17 can promote joint inflammation and bone erosion, but not cartilage destruction 
(van den Berg et al. 2007). In arthritic mouse models, blocking of  IL-17 prevents joint 
inflammation and bone erosion by decreasing RANKL and IL-1 (Koenders et al. 2005) and, 
conversely, overexpression of IL-17 worsens joint inflammation and bone damage (Lubberts 
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et al. 2002). Recently a new subpopulation of helper T cells, which produces IL-17 but not 
IFN-γ or IL-4, was shown in RA synovium and it is these cells which are now called Th17 
cells (Aarvak et al. 1999, Yamada et al. 2008). However, these cells form only a minor 
subpopulation in RA synovitis tissue. It has been suggested, that sets of different cytokines 
and cells producing them are implicated in different stages of RA disease, which is supported 
by observations showing that IL-4 is expressed only in the early stage of the disease and IFN-
γ expression varied depending on the state of RA (Dolhain et al. 1996, Raza et al. 2005).  
 
4.2 Proteinases involved in tissue destruction in RA 
 
Proteolytic pathways play major roles in the development of tissue lesions in RA. 
Degradation of extracellular matrix proteins is essential to pannus formation and invasion. 
Increased production of proteinases has been shown to be involved in many types of cancers 
and inflammatory diseases. Proteinases are responsible for hydrolytic cleavage of peptide 
bonds and are referred as exopeptidases or endopeptidases depending on the cleavage site 




Figure 5. Classification of proteinases based on the molecular site of action on the substrate, 
intra- and/or extracellular localization and pH optimum and structure of the active site. 
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cleavage site at the aminoterminal end and carboxypeptidases with a cleavage site at the 
carboxyterminal end. Endopeptidase cleavage site is located in the middle of the substrate 
molecule. Such endopeptidases can be subdivided based on their catalytic mechanism 
reflected in the involvement of different chemical groups in their active sites. Aspartate, 
cysteine and threonine subtypes act usually intracellularly in acidic environment, whereas 
serine and metallo subtypes act extracellularly in neutral environment. Proteinases are 
involved in diverse biological processes such as digestion, blood coagulation, synthesis and 
activation of proteins, tissue remodelling in e.g. bone and cartilage, immune functions, 
ontogeny and apoptosis (Chang and Werb 2001). Many studies have been made concerning 





The metzincin superfamily belongs to zinc dependent metalloproteinases and is further 
divided into serralysins, astacins and in man important matrixins and adamalysins (Stocker 
and Bode 1995). The matrixins comprise MMPs. Adamalysins ADAMs and ADAMTSs are 
similar to the matrixins in their metalloproteinase domains, but also contain a unique 
disintegrin domain (Figure 6) (Duffy et al. 2003, Jones and Riley 2005). Various mechanisms 
are involved in the regulation of proteinases, including transcriptional and translational 
control, proenzyme activation, transportation and stabilization, inhibition or degradation of 
active enzymes. MMPs and ADAMs contain a prodomain with a “cysteine-switch”, which 
keeps the metalloproteinase site inactive (Nagase 1997). The active site contains a cysteine 
bound zinc atom, which is also coordinated to three conserved histidine residues. Upon 
release of the cysteine block, e.g. upon proteolytic removal of the activation pro-peptide 
containing the blocking cysteine residue, the active site of the enzyme is able to bind a water 
molecule necessary for the hydrolytic processing of the peptide bonds in the protein 
substrates. MMPs, ADAMTSs and many of ADAMs share this common zinc binding 
consensus sequence HEXGHXXGXXH followed by a methionine within the catalytic 
domain. In arthritic diseases, MMPs and adamalysins are considered to be the main enzymes 
responsible for degradation of aggrecans and collagens in cartilage, while some cathepsins 
and ADAMs seem to be involved in bone degradation. 
 
 





Figure 6. Structure and function of matrixins and adamalysins. TM, transmembrane; EGF, 




MMP (matrix metalloproteinase) family proteins include both secreted and membrane bound 
proteinases with at least three shared domains (Figure 6), including the proteolytic domain 
involved in enzymatic digestion of the substrate(s). Wide varieties of tissues express MMPs, 
which are found in cells of both mesenchymal and hematopoietic origins, and these enzymes 
are involved in several physiologic and pathologic processes, including embryonic 
development, tissue morphogenesis, tumor invasion, cancer, angiogenesis, wound healing, 
and inflammatory diseases. Until now, 23 different MMPs have been identified, often divided 
into five subgroups, collagenases, gelatinases, stromelysins, matrilysins and membrane-type 
according to substrate specificity, structure and cellular localization (Martel-Pelletier et al. 
2001). The MMP family members are best known for their ability to cleave components of 
the extracellular matrix, including the collagen, proteoglycan, fibronectin, and laminin, all of 
which are present in the connective tissues of the joints (Martel-Pelletier et al. 2001), but in 
addition to this they also can proteolytically activate other proteinases. Proteolysis often 
occurs in peri-cellular pockets close to the cell membrane, where localization of MMP 
concentrates enhances activity but limits the proteolysis to distinct pericellular regions. 
MMPs have some innate specificity for particular cleavage sites, but colocalization of the 
proteinases and their substrate also play a role in substrate selection (Turk et al. 2001). 
MMPs that have a furin recognition sequence are often activated already intracellulary within 
the Golgi complex and secreted in an active form, but most are secreted as inactive 
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proproteins which are activated extracellularly via cleavage by other extracellular proteinases 
or non-proteolytic release of the cysteine block. MMPs can be activated by serine 
proteinases, such as plasmin (Cawston and Wilson 2006), and also by each other (Murphy et 
al. 1987). All active MMPs are inhibited by tissue inhibitors of metalloproteinases (TIMPs) 
that bind tightly to active MMPs in a 1:1 ratio, but TIMPs can also considered as MMP 
carrier proteins or they may focalize some MMPs to a cell surface MT-MMP/TIMP complex.  
 
Fibril-forming collagens are very resistant to most proteinases because of their rope-like 
triple-helical structure. Three collagenases, MMP-1, MMP-8, and MMP-13, but also MMP-2 
and MT1-MMP, can degrade main type I, II and III fibrillar collagens at a specific initial 
cleavage site right across the triple helix at 775Gly-776Leu/Ile, which produces distinctive 
three-quarter- and one-quarter-sized degradation fragments. These collagenases, however, 
differ in their specificity for different collagen types. MMP-13 prefers type II collagen, 
whereas MMP-1 prefers type III and MMP-8 type I collagen. After the collagen monomer 
has been degraded, its helical structure is spontaneously in the body temperature unwound to 
a random coil, i.e. denatured into gelatin, which is further digested into smaller peptides by 
gelatinases, like MMP-2 and MMP-9. Stromelysins MMP-3 and MMP-10 can degrade 
proteoglycan core proteins, laminins, fibronectin, elastin, gelatin, and collagen types III, IV, 
V, VII, and IX. These two MMPs have similar substrate specificities, but different tissue 
localizations. Degradation of cartilage and bone matrix proteins by MMPs and cathepsins is 
the hallmark of synovial joint destruction. Many MMPs have been shown to be associated 
with RA and especially their involvement in cartilage destruction has been studied (Murphy 
et al. 2002). A beneficial role of some of the MMPs in the regulation of inflammation has 
been reported and their potential anti-inflammatory effect and protective role in RA has been 
emphasized (Gueders et al. 2005). A wide variety of MMP knock-out and transgenic mice 
models have been developed and lots of data, both for and against, have been gained of their 




ADAMs (a disintegrin and metalloproteinases) also referred as MDCs (metalloproteinase 
disintegrin cysteine-rich proteins) are integral transmembrane proteins expressed primarily in 
monocyte/macrophages possessing both proteolytic and adhesive domains. Some ADAMs 
can also be spliced to form soluble proteins or, alternatively, can be shed from membrane to 
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form a soluble form. In mammals, many ADAMs are expressed in the testis and associated 
structures, while others, like ADAM8, ADAM9 and ADAM12, have more widespread 
somatic distribution. The presence of the multiple domains suggests involvement of ADAMs 
multiple functions, including proteolysis, adhesion, cell fusion and cell signalling (Stone et 
al. 1999). Nowadays up to 40 different ADAM peptidases are known and at least half of them 
contain the metalloprotease consensus sequence HEXGHXXGXXHD (Wolfsberg et al. 
1995), which forms a zinc binding active site (Figure 6). ADAMs can also be classified as 
sheddases, because they cleave or shed extracellular parts of transmembrane proteins, e.g. 
cytokines and growth factors, with their metalloproteinase domain being also involved in 
degradation of extracellular matrix (Moss and Lambert 2002). The disintegrin domain is 
involved in adhesion events and interacts with integrins or other cell surface and extracellular 
matrix proteins (White 2003) to bring cells into close contact with other cells or matrix 
components but may also focus metalloproteinase domain into its site of action. Most 
ADAMs do not have conserved RGD integrin-binding consensus sequences so the 
associations then occurs in a RGD-independent manner (Eto et al. 2002). The cystein-rich 
domain in some ADAMs contains a putative fusion peptide, which has been proposed to be 
involved in at least two important cell-cell fusion processes, sperm-egg and myoblast fusion 
(Blobel et al. 1992, Yagami-Hiromasa et al. 1995). At the same time, the wide tissue 
distribution of ADAMs suggests participation also in other cell fusion events and, indeed, 
involvement in osteoclast formation has been reported (Abe et al. 1999, Namba et al. 2001). 
The cystein-rich domain is also implicated in adhesion and might cooperate with proteinase 
domain to control its function (Smith et al. 2002). ADAMs are usually activated by removal 
of the prodomain with furin or other proprotein convertases, but some seem to be also at least 
in part autocatalytically activated (Schlomann et al. 2002). Some ADAM proteins can be 
cleaved between pro-metallo sites to display metalloproteinase activity, followed by further 
cleavage between the metallo-disintegrin sites, which release the adhesion/fusion active 
disintegrin domains. Differences in the activity and subcellular localization depend on the 
ADAM, the cell type expressing it and substrates available. Some pathological conditions, 
such as inflammation, arthritis and cancer, have been shown to involve members of the 
ADAM family. In RA increased expression of cytokines, like TNF-α, has been shown and the 
release of this and other cytokines via shedding mediated by ADAMs may take part in the 
pathogenesis of the disease.   
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ADAM8 (CD156a, MS2) was originally cloned from mouse macrophages (Yoshida et al. 
1990) and is expressed mainly in cells of the immune-inflammatory system, such as B cells, 
monocytes and granulocytes (Yoshiyama et al. 1997). ADAM8 is processed by autocatalysis 
into two different active forms. The processed form is produced by removal of the 
prodomain, whereas the remnant form is derived from it by a further removal of the 
metalloproteinase domain (Schlomann et al. 2002). Additional proteolytic cleavage between 
EGF and transmembrane domain results in two soluble forms, the complete ectodomain and 
the metalloproteinase domain. ADAMs are usually activated by furin-catalyzed removal of 
the prodomain, but for ADAM8 this step is dependent on a metalloproteinase (Schlomann et 
al. 2002), and occurs in part autocatalytically, but may need pre-processing of the prodomain 
(Hall et al. 2009a). The enzymatic activity of ADAM8 is not inhibited by tissue inhibitors of 
matrix metalloproteinases (TIMPs), which is the case for nearly all other membrane-
associated metalloproteinases (Amour et al. 2002). Expression of catalytically active 
ADAM8 is associated with increased invasive activity and extracellular matrix remodeling 
(Wildeboer et al. 2006) and may have an important role in bone morphogenesis (Choi et al. 
2001), possibly via its adhesion and/or fusion effects mediated via integrin receptors on the 
forming osteoclasts (Rao et al. 2006). Increased ADAM8 expression has been shown in 
synovial-like interface tissue around loosened hip prostheses (Mandelin et al. 2003a). 
ADAM8 deficience in mice did not cause any major defects during development or adult 
survival and was not associated with any pathological phenotypes (Kelly et al. 2005).  
 
ADAM9 and ADAM12 were first found to be expressed in neonatal muscle and bone and 
adult bone (Yagami-Hiromasa et al. 1995). Further studies showed that mice lacking 
ADAM9 developed normally and did not show any major pathological phenotypes 
(Weskamp et al. 2002), while ADAM12 deficient models suggest that it plays a role in 
adipogenesis and myogenesis (Kurisaki et al. 2003). Increased expressions of both ADAM9 
and ADAM12 have been implicated in synovial-like interface membrane around aseptically 
loosened total hip replacement implants (Ma et al. 2005, 2006). Both of these proteins have 
been shown to function as fusion proteins during multinucleated giant cell and osteoclast 
formation (Abe et al. 1999, Namba et al. 2001) and ADAM12 also in myoblast formation 
(Yagami-Hiromasa et al. 1995), which might suggest an eventual role in diseases 
characterized by bone tissue destruction. Beside expression in monocyte/macrophages, they 
are also expressed in osteoblast, the most abundant cell type in bone (Harris et al. 1997, 
Mohan et al. 2002). 





Members of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) 
family are secreted enzymes widely expressed in both healthy and pathologic connective 
tissues. The catalytic domains of various ADAMTS proteinases share a high degree of 
similarity and contain the zinc-binding consensus sequence HEXXHXXGXXH, in which the 
catalytic zinc is coordinated by the three histidine residues. Unlike ADAM proteins, 
ADAMTS proteinases contain a conserved thrombospondin type 1-like repeat, between the 
disintegrin-like and cysteine-rich domain, which can be involved in binding to extracellular 
matrix (Kuno et al. 1997; Figure 6). It appears that the zymogen form of ADAMTS enzymes 
resides intracellularly and that the enzyme is activated upon secretion by a furin-catalyzed 
process. Activation of ADAMTSs via a cysteine switch mechanism, which mediates 
activation of most MMPs, has not been proven. At least some of the ADAMTSs can be 
inhibited by TIMP-3. Many of ADAMTSs have been found to be expressed in cartilage 
(Kevorkian et al. 2004) and they influence several inflammatory processes and are involved 
in cartilage metabolism and pathology. ADAMTS proteinases were first described in mice 
(Kuno et al. 1997) and by now 19 different ADAMTSs have been identified, which are 
further divided into small subgroups based on their structural characteristics and activities, 
e.g. aggrecanases involved in cartilage aggregan degradation form one such subgroup 
(ADAMTS-1, -4, -5, -8 -9 -15 and -20). The degradation of the aggrecan molecules by 
aggrecanases might be an early event in articular cartilage degeneration (Nagase and 
Kashiwagi 2003) so that MMPs are later engaged to degrade collagen matrix, suggesting that 
aggrecan protects collagen fibrils from direct degradation by collagenases (Pratta et al. 2003). 
The expression of the entire ADAMTS subfamily has been investigated in normal and OA 
cartilage (Kevorkian et al. 2004) and results provide data suggesting that many members of 
the ADAMTS subfamily may have important roles in cartilage tissue homeostasis and 
pathology. 
 
4.2.2 Cysteine proteinases 
 
Cysteine cathepsins are a large family of proteolytic enzymes involved in various biological 
processes and are also associated with many pathological conditions. Significant differences 
in cathepsins expression levels, activities and ratios have been described between various 
tissues. Man has eleven members of this endoproteinase family, cathepsins B, C, F, H, K, L, 
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O, S, W, X and Z (Zavašnik-Bergant and Turk, 2007). Cathepsins are mainly intracellular 
enzymes expressed in lysosomes of the endocytic pathway and capable to degrade native 
collagens and other components of the extracellular matrix in phagosomes. They have 
homologous amino acid sequences and 3D structures and an active site comprised of 
cysteine, asparagine and histidine residues. To control enzymatic activity cathepsins are 
synthesized as inactive zymogens, which are activated by proteolytic removal of the N-
terminal propeptide or activation peptide. Activation is carried out proteolytically by other 
active enzymes or proceeds autocatalytically (Brömme et al. 1996, McQueney et al. 1997). 
Their stability and activity is dependent on the acidic pH prevailing in lysosomes, Howship’s 
lacunae under the osteoclasts and stomach. Cathepsin K is possibly the most significant 




About forty years ago it was found that proteinases involved in the degradation of the organic 
bone matrix are lysosomal acidic hydrolases (Vaes 1968). The identity of this enzyme named 
cathepsin K was first later discovered, first in rabbit osteoclasts (Tezuka et al. 1994) and 
afterwards the corresponding human cDNA was cloned independently by several groups 
(Brömme 1998). Cathepsin K is also expressed extracellularly and is capable to degrade 
native fibrillar collagen, but also several other components of the extracellular matrix and is 
involved in bone remodeling. The activation of cathepsin K has been shown to occur 
intracellularly, before secretion into the extracellular matrix (Dodds et al. 2001). Classical 
mammalian collagenases of the MMPs family have an initial specific cleavage site at 775Gly-
776Leu(Ile), but cathepsin K is capable to cleave the triple helical collagen domains at 
multiple sites a bit like bacterial collagenases (Garnero et al. 1998). Predominantly cathepsin 
K is expressed in skeleton, but lower levels are found in other tissues because it is also 
expressed by synovial fibroblasts, synovial macrophages, chondrocytes of the articular 
cartilage, osteoclasts and osteoblasts (Rantakokko et al. 1996, Hou et al. 2001, Mandelin et 
al. 2006, Salminen-Mankonen et al. 2007). The best known role of cathepsin K is its 
involvement in osteoclast-mediated resorption of the demineralized organic bone matrix. This 
is due to its high collagenolytic activity, especially against type I collagen (Brömme et al. 
1996), and its location in sites with low pH found in the resorption lacunae of osteoclasts 
(Yamaza et al. 1998) (Figure 1), but also in the acidic interface membrane surrounding 
loosened hip prosthesis implants (Konttinen et al. 2001). 
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Much of our current understanding on the role of cathepsin K in bone destruction derive from 
the usage of various genetically manipulated mouse models (Gowen et al. 1999, Saftig et al. 
2000, Morko et al. 2005, Li et al. 2006), in which an arthritis has been superimposed 
(Salminen-Mankonen et al. 2007). Further information derived from pathological conditions 
involving bone and cartilage turnover, such as osteoporosis, osteoarthritis, osteopetrosis, 
osteosclerosis and RA (Vasiljeva et al. 2007). The basic observations demonstrate 
accelerated bone turnover and reduced trabecular bone volume in conditions characterized by 
an increased cathepsin K expression, whereas targeted disruption of cathepsin K results in 
osteopetrotic conditions and bone fragility (Kiviranta et al. 2001). Cathepsin K as also 
cathepsins S, B and L levels are increased in synovial fluid and lining indicating a potential 
role in initiation and/or progression of RA (Reddy et al. 1995, Liao et al. 2004, Yasuda et al. 
2005). Cathepsin L might also play a role in bone resorption (Iwata et al. 1997), but the role 
of other cysteine cathepsins, beside the cathepsin K, in pathological degradation of 
extracellular matrix remains unknown. The proof for the major role for cathepsin K in bone 
collagen degradation was provided by the discovery that deficiency of this enzyme causes a 
rare autosomal bone disorder called pycnodysostosis. 
 
Cathepsin K deficiency 
 
Pycnodysostosis is a rare genetic disease of the bone with the main characteristic features 
being a short stature and fingers, with slow but progressive deterioration and densification of 
bones with a tendency to fractures (Maroteaux and Lamy 1962). The name "pycnodysostosis" 
describes well this disease as formation of abnormally dense (pykno) bone. The precise 
frequency of pycnodysostosis has never been determined, but it is quite well known for the 
late 19th century French poster artist Henri de Toulouse-Lautrec (1864 – 1901), so much so 
that this disease is sometimes referred as Toulouse-Lautrec Syndrome. His diagnosis has 
been made retrospectively from old photographs because his size, body proportions and 
health problems fit well with the characteristics of pycnodysostosis. 
 
Pycnodysostosis is an autosomal recessive disease, in which the gene is situated on one of the 
non-sex chromosomes and two copies, one from each parent, is needed for disease 
development. The chromosomal localization of the gene responsible for pycnodysostosis was 
first mapped in 1995 into chromosome region 1q21 and once the location was identified, the 
potential genes were evaluated, and one of those was cathepsin K (Gelb et al. 1995). In 1996, 
 Review of the literature  
36 
 
cathepsin K mutations were linked to pycnodysostosis, which was then concluded to be 
caused by cathepsin K deficiency (Gelb et al. 1996). The phenotypes of cathepsin K knock-
out mice resemble those of the pycnodysostosis patients, although some differences have 
been reported (Kiviranta et al. 2005, Li et al. 2006). 
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5. AIMS OF THE STUDY 
 
The main aim of this study was to understand the role of pannus tissue and involvement of its 
products in cartilage and bone degradation in RA. 
 
1. Matrix metalloproteinases have been implicated in extracellular matrix degradation and 
RA is characterized by invasion of inflamed pannus tissue into cartilage and bone matrix. The 
first aim was to characterize all the known MMPs in RA tissue.  
 
2. The second aim was focused to extend the previous one to some of those MMPs, which 
showed a potential role in RA and which were accordingly chosen for a more detailed 
analysis. The aim was to quantitate the expression of these MMPs in RA synovial and pannus 
tissues and to study their potential inducers. 
 
3. Osteoclasts have been implicated in destruction of the subchondral bone in RA and the 
third aim was to characterize the eventual expression of receptor activator of nuclear factor 
kappa B ligand (RANKL), a factor essential for osteoclast differentiation, in pannus tissue.  
 
4. To characterize ADAMs (a disintegrin and a metalloproteinases), newly identified 
metalloproteinases and potential osteoclast-activating factors for their eventual involvement 
in pannus tissue invasion and formation of osteoclast-like multinuclear cells by promoting 
fusion of mononuclear precursor cells. 
  
5. The last aim was to study the role of the major osteoclast proteinase cathepsin K in pannus 
tissue and in cartilage/bone degradation. A cathepsin K deficient patient with 
pycnodysostosis, who had developed a chronic arthritis, was studied and used as “a human 
knock-out” arthritis model in functional analysis. 
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6. MATERIALS AND METHODS  
 
6.1 Patients and samples 
 
6.1.1 Tissue samples (I, II, III, IV) 
 
The research plan was approved by the ethical committee of the Helsinki University Central 
Hospital. Guidelines of the Declaration of Helsinki were followed. RA patients fulfilled the 
revised criteria of the American College of Rheumatology (Arnett et al. 1988). Samples of 
RA synovitis tissue and pannus attached to cartilage/bone at sites of erosions were collected 
in parallel from patients undergoing total joint arthroplasty, synovectomy or arthroscopy. 
Control synovial tissue samples were obtained from traumatic patients undergoing 
arthroscopy or OA patients undergoing total hip arthroplasty. Traumatic injuries may induce 
a cascade of events which leads to local inflammation. Traumatic synovitis display more 
layers of lining cells and infiltrating inflammatory cells than healthy tissue, however, 
compared to RA, these findings were limited and inflammation after trauma is usually self-
limiting and will resolve. OA was selected as one of the controls because it is characterized 
by cartilage degeneration and wear-and-tear, but relatively mild secondary synovitis and is 
thus distinguished from RA. None of the patients included in the present study had any 
clinical or microbiological signs of infection. The samples were during operation snap-frozen 
in dry ice precooled isopentane and stored at -70ºC until further processing.  
 
6.1.2 Pycnodysostosis patient (V) 
 
The patient was a 55 year old woman with short stature, only 143 cm, and had had several 
pathological bone fractures. Her right femur had altogether fractured for five times and left 
for four times. Her finger bones and the middle metatarsal bone were very short and had also 
undergone pathological fractures, which is a feature typical for pycnodysostosis. On the basis 
of these symptoms in 1976 the Clinic for Inherited Diseases diagnosed her to suffer from an 
autosomal inherited pycnodysostosis. In 1994 our patient developed arthritis. After remission 
in 1995, bone scanning confirmed arthritis in several joints and signs of several previous 
fractures. Because earlier psoriatic skin eruptions, her arthritis was considered psoriatic 
arthritis, characterized by erosions and ostelysis of the tips of the small bones, and anti-
rheumatic medication was started. Recently also markers for rheumatoid arthritis and 
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inflammation have been detected; the main thing from the point of view of the current work, 
however, is that she has some form of chronic arthritis. Her arthritis continued to lead 
progressively to the development of bone erosions, acro-osteolysis and osteolysis of the 
phalanges in her joints and bones. Her parents, children or sisters do not suffer from this 
disease. 
 
6.1.3 Cell culture  
 
Fibroblasts extraction and stimulation (II, III) 
Fibroblasts from RA and OA patients were established using explant culture method. Tissue 
samples were minced to small pieces and left over night in cell culture media containing 10 
% fetal bovine serum (FBS) (BioWhittaker) and high 10% antibiotic concentrations (1000 
U/ml penicillin and 1 mg/ml streptomycin) to elude microbe contamination. Next day the 
media was changed and the concentration of antibiotics was decreased to normal 1 % 
concentration. The media was changed twice a week. Fibroblast-like cells started to migrate 
out from the tissue explants and after approximately 2 weeks, when 60 % of the dish area was 
covered with monolayer of cells, the tissue pieces were removed and the cultures were either 
allowed to grow to confluence when used for analysis or split 1:6 using trypsin detachment 
for maintenance. Cells were characterized with immunofluorescence staining of fibronectin 
and vimentin and were used at passages 3-6. Cell numbers were counted using Z1 Coulter 
Particle Counter (Beckman Coulter) in a sample defined 17-27 μm window. For stimulations, 
cells were cultured to confluence in 6-well plates at 1x105 cells per well. The cells were 
stimulated with different concentrations of recombinant human (rh) cytokines for various 
times: 1) TNF-α (R&D), 2) IL-1β (R&D) or 3) IL-17 (R&D). Two parallel wells were used 
for RNA extraction and one well with 4 coverslips for histochemical and 
immunohistochemical analysis.  
  
Human monocyte isolation and stimulation (III, IV, V) 
Human monocytes were isolated from freshly drawn peripheral blood using Ficoll-Paque 
density gradient (Pharmacia Biotech) to separate mononuclear cells from red blood cells and 
granulocytes. Cells were counted using Z1 Coulter Particle Counter (Beckman Coulter) in a 
sample defined 6-16 μm window. Cells were cultured in a 6-well plates at 1x106-1x107 cells 
per well in 2 ml or in a 24-well plate at 5x105-1x106 cells per well in 0.5 ml in MEM Alpha 
Medium with Glutamax-1 (Invitrogen) supplemented with 10 % FBS and 1 % antibiotics.  
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After one hour incubation the non-adherent cells containing predominantly lymphocytes were 
removed and the adherent monocyte/magrophage-enriched cultures, characterized by 
monocyte (CD14) and macrophage (CD68) markers, were further stimulated with different 
concentrations of human recombinant cytokines for various times: 1) TNF-α (R&D), 2) IL-1β 
(R&D), 3) IL-17 (R&D), 4) M-CSF (R&D), 5) RANKL (Alexis Biochemicals) or 6) a 
combination of IL-1β, M-CSF and RANKL. (III, IV, V) 
 
Adherent monocytes/macrophages were also used for co-culture with fibroblasts, which were 
added together with 40 ng/ml rhM-CSF (R&D) and with or without different concentration of 
rhTNF-α, rhIL-1β, rhIL-17 (R&D) or rhRANKL (Alexis Biochemicals) for various times. 
(III)   
 
Mouse monocyte/macrophage cell line (IV)   
RAW 264.7 mouse monocyte/macrophages (TIB-71, ATCC) were cultured in high glucose 
DMEM (Gibco) with 10 % FCS and 1% antibiotics. Cells are refreshed twice a week and 
split 1:6 once a week using scraping without trypsination for detachment. Cells were cultured 
in 6-well plates at 1x105 cells per well in 2 ml or in a 24-well plate at 5x104 cells per well in 
0.5 ml medium. Cells were counted using Z1 Coulter Particle Counter (Beckman Coulter) in 
a sample defined 8-14 μm window at passages 4-10.  
 
Osteoclast formation and resorption (III, IV, V) 
Human and mouse monocyte/macrophages were used to generate multinuclear osteoclast-like 
cells by fusion. Adherent human monocytes were stimulated with 1) rhM-CSF (25ng/ml, 
R&D), 2) RANKL (40 ng/ml, Alexis Biochemicals) and 3) transforming growth factor β1 
(TGF-β1, 5ng/ml, R&D) to generate osteoclasts in 14 day cultures. Adherent RAW 264.7 
mouse monocyte/macrophages were stimulated with glutathione-Sepharose column purified 
GST-RANKL (100 ng/ml) to induce osteoclasts formation in up to 9 day cultures. 
Multinuclear cells were stained for TRAP using leukocyte acid phosphatase kit (387-A, 
Sigma), which generates a dark purple colour. 
 
The capability of the multinuclear cells to resorb bone was analyzed by culturing stimulated 
human and mouse monocyte/macrophages at 5x105 and 5x104 cells per well, respectively (as 
above), on dentine discs (Immunodiagnostic Systems Limited, IDS) in 96-well plates. Cells 
were stained for TRAP (as above) and after visualization brushed away for inspection of the 
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resorption pits formed on the dentin discs using toluidine blue staining (3 minute incubation 
in 1% Toluidine Blue, 1% Na-tetraborate x 10 H2O –solution at room temperature). (V) 
 
All cell culture work was done at least in triplicates. 
 
6.2 RNA expression 
 
6.2.1 RNA extraction and cDNA synthesis (I-V) 
 
Total RNA from frozen tissue and cultured cells was isolated using TRIzol reagent 
(Invitrogen). Tissue samples were homogenized using a small blade in the Ultra-Turrax 
homogenizer (Janke & Kunkel, IKA-Labortechnik) until the tissue formed an even 
suspension and cells were lysed without homogenization in TRIzol solution. This mono-
phasic solution of phenol and guanidine isothiocyanate maintains the integrity of the RNA, 
but disrupts cells and dissolves cellular components. Chloroform was added before 
centrifugation to separate RNA into the aqueous phase, from where it was recovered by 
precipitation with isopropyl alcohol. Intactness of the RNA isolates was controlled using 
ethidium bromide staining of 1% agarose gels after electrophoresis. After extraction of total 
RNA, mRNA was further isolated from this RNA solution using oligo(dT)25 oligonucleotides 
covalently attached to magnetic polystyrene microbeads via 5' linker group (Dynal) to reduce 
the genomic DNA contamination and to improve the subsequent yield of specific cDNAs. 
The procedure relies on A-T base pairing, where oligo-dT oligonucleotides hybridize with the 
polyA tail of mRNA followed by separation of the mRNA containing beads with magnet. 
Messenger RNA extraction was controlled with spectrophotometric measurement. 50 or 100 
ng aliquots of mRNA were reverse transcribed to cDNA with SuperScript™ Preamplification 
System (Invitrogen). It utilizes oligo(dT) for hybridization to the purified 3´ poly(A) tails of 
mRNA isolates, followed by first-strand cDNA synthesis with reverse transcriptase (RT) 
enzyme and removal of mRNA template with RNase H treatment. Extraction and 
transcription were controlled using housekeeping genes. Negative PCR controls were 
performed without RT enzyme or sample mRNA, whereas positive controls were performed 
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6.2.2 Design of primers and probes for PCR (I-V) 
 
Gene sequences were searched from NCBI Entrez search system. Sense and antisense 
primers and PCR probes were designed using primer design software Primer3 (Rozen and 
Skaletsky 2000). Primers were usually 20 nucleotides and were designed to minimize primer 
dimers and complementary regions, not to contain over 3x nucleotide repeats, to have 45-55 
% GC concentration and Tm 60°C. Probes were 26-30 bases long and were designed to have 
Tm 10°C higher than that of the primers, to contain the reporter dye on the 5’ end and the 
quencher dye on the 3’ end (Table 2).  
 
Sequence similarity searches for right primer/template and probe sequences and template 
exon/intron breaks were done using NCBI blastn program. Primers and probes were produced 
by Oligomer (Helsinki, Finland) or Proligo (Paris, France). The identity of the product was 
verified by size after PCR amplification (Dynazyme, Finnzymes) and by sequence from 50 ng 
of isolated (QIAquick, Qiagen) amplicon using automated Applied Biosystems 373 A 
sequencer in Sequencing Core Facility in Haartman Institute (Helsinki, Finland). 
 
For TaqMan-based technology, the primers were designed to be located inside one exon to 
allow the use of genomic DNA as a standard (III). Probes anneal to minus strand and had 
reporter dye FAM (6-carboxy-fluorescein) at the 5’ end and quencher dye TAMRA (6-
carboxy-tetramethyl-rhodamine) at the 3' end, which was also phosphorylated. For SYBR 
green (II, IV, V) the primer sets were designed to be located in different exons, with at least 
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6.2.3 Cloning for qPCR and design of in situ hybridization probes (II-V) 
 
For quantitative PCR standard curve and probes for in situ hybridization a specific PCR 
product was inserted into plasmid and grown in bacterial culture to produce large quantities 
of target DNA. Briefly, the gene of interest was first amplified with specific primers and 
extracted from agarose gel. The PCR-amplified fragment containing 3' deoxyadenosine-
overhangs was cloned to a topoisomerase I activated, linearized pCR®II TOPO vector with 
single, overhanging 3' deoxythymidine residues using TOPO TA Cloning® kit (Invitrogen). 
Cloned vectors were transformed into chemically competent E.Coli bacteria using heat shock 
and plasmids containing the insert were selected with X-gal white/blue screening on LB 
plates. Positively selected plasmids from blue colonies were grown overnight in Luria-
Bertani (LB) media and isolated, followed by linearization of the constructs with restriction 
enzymes. The plasmids with insert were identified by gel electrophoresis after restriction 
enzyme digestions, with PCR amplification and sequenced from 1 μg of isolated DNA. The 
acquired sequence was verified with NCBI blastn program and the concentrations of the 
plasmids were analyzed spectrophotometrically.  
 
For in situ probes, plasmid DNA was linearized using either Xho I or Hind III (New England 
Biolabs) restriction enzymes. DNA templates were ethanol precipitated and in vitro 
transcribed to either single-stranded antisense RNA probe using SP6 RNA polymerase or a 
sense RNA control probe using T7 RNA polymerase. Digoxigenin-conjugated UTP (DIG 
RNA Labeling Kit, Roche) was incorporated into the RNA probes during synthesis, which 
was followed by digestion of the DNA template with RNase-free DNase I. The orientation of 
the insert was determined by sequencing using M13 reverse and forward primers. (IV) 
 
6.2.4 Conventional RT-PCR (I-V) 
 
PCR amplification was performed using 1 μl (2.4 or 4.8 ng) of first strand cDNA (6.3.1), 0.4 
mM of target specific primers (section 6.3.2), dNTP mix and 2U of the thermostable DNA 
polymerase (Finnzymes) or AmpliTaq Gold enzyme (Applied Biosystems) in 50 µl of PCR 
buffer. The reaction was run in a thermal cycler (RoboCycler 40 Temperature Cycler) for 
40 cycles using one minute denaturation at +95°C, one minute annealing at the optimal 
temperature, one minute extension at +72°C and finally 10 minutes extra extension for the 
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last cycle. Amplifications without template, or without both template and primers, were 
performed as negative PCR controls. Amplified DNA was run on a 1% agarose gel and 
visualised with ethidium bromide under UV-light for size verification.  
 
6.2.5 Quantitative RT-PCR (II-V) 
 
Quantitative PCR amplification was performed using 2 μl (4.8 or 9.6 ng) of first strand 
cDNA, 0.25 mM of target specific primers (section 6.3.2) in LightCyclerTM FastStart DNA 
Master Hybridization Probes or SYBR Green I PCR mix in LightCyclerTM PCR machine 
(Roche). A serial 1:10 dilution of human genomic DNA for hybridization probes or cloned 
PCR fragments for SYBR Green were used to determine the mRNA copy numbers of the 
amplicons per housekeeping gene β-actin or porphobilinogen deaminase (PBDG). Copy 
numbers of the genes were calculated by the number of grams/molecules of the plasmid that 
contains the gene of interest. With SYBR green mix, the identity of the product was also 
verified by a melting curve analysis. Each individual sample was amplified at least two times 
for all genes of interest. 
 
6.2.6 In situ hybridization (IV) 
 
In situ hybridization was performed to localize and detect mRNA expression in tissue 
sections by hybridizing the labelled complementary RNA strand (antisense probe) to the 
sequence of interest. Frozen tissue sections (6 μm) were first fixed in acetone and after air 
drying refixed in 4 % formaldehyde. After washes the sections were incubated in acidic 10 
mM sodium citrate, pH 6.0, at 80-90°C for 60 minutes for antigen retrieval, rinsed in buffer, 
and treated to block the polar groups using TEAA (0.1 M triethanol amine, pH 8.0, with 
1:400 (v/v) acetic anhydride). Following dehydration in ethanol, sections were incubated in 
hybridization buffer (50 % deionized formamide, 10 % dextran sulfate, 1 x Denhardt's 
solution, 100 μg/ml yeast tRNA, 300 mM NaCl, 10 mM Tris-HCl, pH 7.6, 5 mM EDTA and 
10 mM NaH2PO4) at 56°C for 60 minutes followed by incubation in hybridization buffer 
containing 1-2 ng/μl of digoxigenin-labeled antisense or control sense RNA probes at 56°C 
overnight in humid boxes. After posthybridization washes unbound single-stranded RNA was 
digested with RNase A. RNA hybrids were visualized using alkaline phosphatase-conjugated 
sheep anti-digoxigenin Fab (Roche), with the colour being developed in bromochloroindolyl 
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phosphate (BCIP), nitroblue tetrazolium (NBT) and levamisole followed by counterstaining 
in methylene green.  
 





Paraffin embedded tissue samples: Serial 3 μm thick sections were dried overnight and 
deparaffinizated. Staining was performed in DAKO TechMateTM Automated Immunostainer 
500 and processed at 22°C using DAKO ChemMateTM Reagent System. The protocol 
followed MSIPE program with 30 minutes enzymatic digestion in 4 mg/ml pepsin for antigen 
retrieval and 1 hour incubation with primary antibody. The concentrations of the primary 
antibodies used were as follows: 10 μg/ml for mouse anti-human RANKL IgG2b (R&D), 0.67 
μg/ml for mouse anti-human MMP-1 IgG2a/κ (Chemicon) and 2.5 μg/ml for mouse anti-
human MMP-3 IgG1/κ (Chemicon). The level of nonspecific immunoreactivity was 
determined using same concentration of isotype-matched antibodies derived from the species 
used to generate the primary antibodies. Endogenous peroxidase activity was blocked with 
0.3% peroxidase solution. Staining was visualized using biotinylated secondary antibody 
against the IgG of the host species of the primary antibody and visualized using horseradish 
peroxidase-conjugated streptavidine, with H2O2 as substrate and diaminobenzidine (DAB) as 
dye. Nuclei were stained purple using hematoxylin counterstain. Hematoxylin and eosin 
stained was used for morphological evaluation of tissue samples, where intracellular and 
extracellular proteins are stained with eosin. (II, III) 
 
Frozen tissue samples: 6 μm tissue sections were fixed in acetone and endogenous peroxidase 
activity was blocked with 0.3 % H2O2. The sections were blocked with normal goat serum 
(Vector Laboratories) and stained with a polyclonal rabbit antiserum recognizing 
cysteine/disintegrin domain of mouse ADAM8 (Choi et al. 2001), whereas the same 
concentration of nonimmune rabbit IgG (Dako) was used as negative control. Staining was 
visualized with biotinylated goat anti-rabbit IgG, followed by avidin-biotin-peroxidase 
complex. Peroxidise activity and nuclei were detected as with paraffin tissue sections. 
ADAM8 double staining with TRAP was done using TRAP staining leukocyte acid 
phosphatase kit (Sigma) after ADAM8 immunostaining. (IV) 




Tissue samples fixed with acetone or cell culture samples on coverslips fixed with 3 % 
paraformaldehyde were incubated in primary antibodies: 10 μg/ml mouse anti-human 
RANKL IgG2b (R&D), 10 μg/ml mouse anti-human MMP-3 IgG1/κ (Chemicon), 10 μg/ml 
mouse anti-human ADAM8 IgG2B recognizing metalloprotease-disintegrin domain (R&D 
Systems) or 5 μg/ml rabbit anti-human ADAM8 IgG recognizing catalytic domain (Triple 
Point Biologics). The level of nonspecific immunoreactivity was determined using the same 
concentration of isotype-matched antibodies of the host species of the primary antibody. 
Staining was visualized with fluorescent Alexa Fluor dyes 488 or 594-labeled secondary 
antibody against IgG of the host species of the primary antibody (Molecular Probes). Nuclei 
were stained with 4',6-Diamidino-2-phenylindole (DAPI) (Sigma). (II, III, IV) 
 
In co-cultures of monocyte/macrophages with fibroblasts, the multinuclear osteoclast-like 
cells were stained first for TRAP with leukocyte acid phosphatase kit (Sigma) and nuclei 
were then stained with DAPI (Sigma). (III) 
 
6.3.2 Western blots (II, IV) 
 
Tissue samples were homogenized using the small blade of the Ultra-Turrax homogenizer 
(Janke & Kunkel, IKA-Labortechnik) in RIPA Buffer Set (Boehringer Mannheim), whereas 
cell culture samples were lysed in Passive Lysis buffer (Promega). Samples were 
ultrasonicated in Vibra-Cell 501 (Sonics & Materials), centrifuged and filtrated to remove 
cell debris. SDS-PAGE was performed using 10-75 µg total protein per sample, mixed with 
sodium dodecyl sulfate sample buffer and boiled for 5 minutes for protein denaturation and 
applied to gels.  After electrophoresis, the gels were blotted onto nitrocellulose membrane 
(Bio-Rad Laboratories), blocked overnight in 3 % bovine serum albumin (BSA) and 
incubated in primary antibodies: 0.2 μg/ml polyclonal goat anti-human MMP-1 IgG (R&D 
Systems), 0.2 μg/ml polyclonal goat anti-human MMP-3 IgG (R&D Systems), 2 μg/ml 
monoclonal anti-human OPG IgG2a (R&D), 0.2 μg/ml biotinylated polyclonal rabbit anti-
human RANKL IgG (PeproTech) or 1 μg/ml polyclonal rabbit anti-human ADAM8 IgG 
recognizing the carboxyterminal end, all diluted in 2 % BSA / Tris-Buffered Saline. 
Detection was performed using alkaline phosphatase-conjugated secondary antibody against 
the IgG of the host species of the primary antibody (Jackson Immunoresearch Laboratories) 
or alkaline phosphatase-conjugated avidin (Sigma) with a colour development solution 
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(Alkaline Phosphatase Conjugate Substrate Kit), with BCIP as substrate and NBT as 
chromogen forming an insoluble black-purple precipitate.  
 
6.3.3 Flow cytometry (IV) 
 
Flow cytometry was used to identify and characterize subpopulations of cells by sorting with 
size, morphology and fluorescent label of markers on the surface of the cells. Cells were 
detached from culture plates and 1x105 cells in 100 μl were incubated with 0.5 μg/ml 
monoclonal mouse anti-human monocyte marker CD14 IgG2a (Dako), 4.5 μg/ml monoclonal 
mouse anti-human macrophage marker CD68 IgG1 (Dako) or 10 μg/ml mouse anti-human 
ADAM8 IgG2B recognizing metalloproteinase-disintegrin domain (R&D Systems), all diluted 
in 1% BSA. The level of nonspecific immunoreactivity was determined using same 
concentrations of isotype-matched IgG of host species of the primary antibodies.  Cells were 
stained with fluorochrome fluorescein isothiocyanate (FITC)-conjugated secondary antibody 
against IgG of the host species of the primary antibody (Jackson ImmunoResearch 
Laboratories) diluted in 1 % BSA. The intensity of fluorescence was measured and analysed 
and the cells were analyzed by flow cytometry using FACScan analyzer with Cell Quest 
software (Becton Dickinson). The results are reported as the percentage of positive cells of all 
cells.  
 
6.3.4 ELISA (II) 
 
Cell culture media were centrifuged to remove cells and cell debris. Supernatants were 
diluted to the optimum working range and the amount of total MMP-3 (pro- and/or active) 
was measured using Human MMP-3 Quantikine ELISA Kit (R&D Systems), in which a 
polyclonal MMP-3 specific antibody has been used to pre-coat the wells of the microwell 
plate. MMP-3 present in supernatant and standard samples was bound by the immobilized 
antibody, and total amount of bound protein was detected with another enzyme-linked 
polyclonal MMP-3 specific antibody. The intensities of colour developed by substrate 
solution were measured at 450 nm using wavelength 540 nm for correction. All the samples 
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6.4 Functional assays 
 
Inhibition (V) 
In vitro analysis of bone resorption was performed also in the presence of a non-specific 
cathepsin K inhibitor E-64 (Sigma) to mimic the cathepsin K deficiency of the cells of the 
pycnodysostosis patient. E-64 is an irreversible, potent and highly selective cysteine protease 
inhibitor that does not affect cysteine residues in other enzymes. E-64 was selected because it 
is a specific cystein endoproteinase inhibitor, which permeates well into cells and tissues, has 
a low toxicity and is stable. The concentration of E-64 recommended by the manufacturer is 
1-10 μM, but we used 0.5-1 μM concentrations because pilot tests showed successful 
formation of multinuclear cells in this range, compared to slightly inhibited formation using 
higher concentrations. Human monocyte/macrophages were cultured on dentine discs 
(section 6.1.3) in the presence of RANKL, M-CSF and E-64 for different times.  
 
Transfection (IV) 
Transfection was used to introduce a cloned ADAM8 DNA into mouse 
monocyte/macrophages for induction of ADAM8 expression. Mouse monocyte/macrophages 
were cultured as described (section 6.1.3) and transfection was performed 24 hours after 
GST-RANKL stimulation using 0.8 μg full length cDNA of mouse ADAM8 in pcDNA3.1/V-
5 vector (a gift from Dr. Choi) and Lipofectamin™ 2000 (Invitrogen). Efficiency of 
transfection was verified using quantitative RT-PCR, expression of green fluorescent protein 
(GFP) and immunofluorescence staining of ADAM8. The effect of transfection on 
multinuclear cell formation was studied using TRAP staining (section 6.1.3).  
 
Silencing (IV)  
Post-transcriptional gene silencing was used to inhibit ADAM8 expression by using short 
RNA probes to base pair (hybridize) with target mRNA, which is under these circumstances 
degraded so that translation to active protein is prevented. Mouse monocyte/macrophages 
were cultured as described (section 6.1.3). Double-stranded ADAM8 and control siRNA with 
a 19-nucleotide complementary region and a 2-nucleotide TT 3' overhang at each end were 
designed and synthesized by Proligo (Paris, France; table 2) for siRNA silencing. Silencing 
was performed twice at 24-hour interval after GST-RANKL stimulation of RAW 264.7 using 
80 pmol siRNA per well and Lipofectamin™ 2000 (Invitrogen) for transfection. Mismatch 
siRNA duplex and Lipofectamin™ alone without siRNA were used as controls. Efficacy of 
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ADAM8 silencing was verified using quantitative RT-PCR. The effect of silencing on 
multinuclear cell formation was studied using TRAP staining (section 6.1.3).  
 
6.5 Image analysis and statistical analysis 
 
Image analysis (II-V) 
Tissue samples, cell cultures and dentine discs with resorption pits were inspected using 
Olympus AX70 microscope and images were acquired with a 12-bit CD camera (SensiCam). 
Images were analyzed using a semiautomatic AnalySis Pro 3.0 image analysis and processing 
software (Olympus). The depths of the resorption pits were determined using a 20x/ 0.70 
numerical aperture (NA) objective for focusing a laser beam in a sample and a Leica TCS 
SP2 AOBS laser scanning confocal microscope on reflection mode (Leica Microsystems AG, 
Mannheim, Germany). 
 
Statistical analysis (II-IV) 
Statistical analysis was performed using GraphPad Prism version 3.02 for Windows 
(GraphPad Software). Paired t test was used for comparison of paired samples. One-way 
ANOVA and nonparametric methods were used for multiple group comparison combined 
with Tukey’s test for all possible pairwise comparisons, comparing the mean of every group 
with the mean of every other group, Dunnett's test for all against a control group and 
Bonferroni's test for only a few comparisons based on our aims. All data are expressed as 
mean and SEM and P < 0.05 was considered to be significant.  
 
6.6. Analysis in other laboratories (V) 
 
Collagen degradation analysis 
Cathepsin K generated bone degradation products (C-terminal cross-linked telopeptide of 
type I collagen = CTx) were analysed using an automatic Elecsys instrument (Roche) or an 
Crosslaps ELISA assay (Nordic Bioscience) and MMP- generated bone degradation products 
(type I collagen carboxyterminal cross-linked telopeptide = ICTP) were analysed with 
radioimmunoassay (Orion Diagnostica) in serum and cell culture samples. Analyses were 
done in Professor Juha Risteli’s laboratory in the Department of Clinical Chemistry (Oulu 
University Hospital, Oulu, Finland) (Risteli et al. 1993). 
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Measurement of active cathepsin K 
Active cathepsin K was measured in Dr. Roeland Hanemaaijer’s laboratory in TNO Quality 
of Life (Biomedical Research, Leiden, the Netherlands) with modified urokinase assay 
(Lindeman et al. 2004). Plates were coated with cathepsin K-specific monoclonal antibody 
(TNO) recognizing native cathepsin K and incubated with cell culture supernatant samples 
for binding of cathepsin K. Activity was measured by incubation of the captured cathepsin K 
with a modified prourokinase variant (UKcatK) in which the endogenous plasmin activation 
site has been adapted to a cathepsin K-specific activation site. Activated UKcatK was 
quantified using a chromogenic peptide substrate (Biosource Europe) and colour 






7. RESULTS AND DISCUSSION 
 
Active inflammation in rheumatoid arthritis causes formation of inflamed tissue (synovitis 
tissue and pannus tissue) which expands and invades into articular cartilage and subchondral 
bone damaging both tissues. Growing pannus cells and tissue are capable of releasing 
proteinases, which promote inflammatory cell invasion and hard tissue destruction. In RA 
hard tissue destruction is thought to be driven by pannus tissue, but the damage to cartilage 
and bone is mediated by distinct patophysiological pathways. Fibroblast-like cells, in co-
operation with macrophage-like cells, are capable of mediating proteolytic cartilage damage. 
Instead, multinuclear bone resorbing osteoclasts, which are found in rheumatoid erosions, can 
directly damage bone, but do not appear to affect cartilage.  
 
7.1 Synovial inflammation and pannus formation (I, II) 
 
MMPs are members of a large proteolytic enzyme family and degrade extracellular matrix. In 
early RA increased expression of MMPs in pannus participates in the invasion of cartilage by 
degrading extracellular matrix and by activating other proteinases. Increased expression of 
some MMPs was shown in RA tissue compared to trauma tissue samples in the first work of 
this thesis and some of these MMPs were analysed in more detail in the second thesis work.  
 
In RA synovitis tissue the most exclusive expression was observed for MMP-13, which was 
not detected in synovial tissue of patients with trauma (Table 3). MMP-13 degrades type II 
collagen particularly well. It is expressed by chondrocytes and synovial cells in RA and 
localized in pannus-hard tissue junction (Lindy et al. 1997, Konttinen et al. 1999b). It has 
 
 
Table 3. mRNA expression on different MMPs in the traumatic (N=9) and rheumatoid 
synovial membrane (N=10) samples. The results of conventional RT-PCR are given as the 
number of positive samples per all samples. 
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been shown that overexpression of MMP-13 increases synovial inflammation, but MMP-13 
was rarely associated with damage of the articular cartilage after intra-articular injection of 
MMP-13 coding adenovirus vector (Joronen et al. 2004), indicating that it may play a role 
during the early phases of arthritis. In the second thesis work quantitative mRNA data on 
MMP-13 showed perhaps a slight tendency to an increase in OA compared to RA, but this 
difference was not significant (Figure 7A). This is in line with the earlier finding that 
chondrocytes produce MMP-13 in OA (Murphy et al. 2002) and with recent observations 
about the key role of MMP-13 in the development of OA (Takaishi et al. 2008). MMP-13 
has, however, been found to be highly expressed in destructive periodontal disease, 
suggesting a role in the periodontal ligament and alveolar bone loss developing in this disease 
(Hernandez et al. 2006), or in osteoblast-mediated bone matrix degradation (Parikka et al. 
2005). MMPs have also been suggested to produce collagen fragments which facilitate 
recruitment and activation of osteoclasts. Expression levels of MMP-13 were lower than 





Figure 7. A) Quantitative mRNA expressions of MMP-1, -3, -13 and -14, normalized for β-
actin in osteoarthritic synovial tissue (ST/OA, n = 9), rheumatoid arthritic synovial tissue 
(ST/RA, n = 9) and pannus tissue (PT/RA, n = 8) in different panels. B) Messenger RNA 
expression levels of MMP-1, -3, -13 and -14 normalized for β-actin in osteoarthritic synovial 
tissue (ST/OA), rheumatoid arthritic synovial tissue (ST/RA) and pannus tissue (PT/RA) 
shown all in the same scale. 
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OA the cartilage destruction is driven by chondrocytes, so also in RA MMP-13 might be 
involved with chondrocyte mediated cartilage destruction rather than invasion of pannus into 
the cartilage.  
 
MMP-14 was expressed in all RA samples, but not in all control trauma samples (Table 3). 
Antisense MMP-14 treatment reduces the invasiveness of synovial fibroblasts and 
degradation of cartilage (Rutkauskaite et al. 2005). MMP-14 has been shown to be expressed 
in the invasive pannus tissue in RA and to be coexpressed in a complex with TIMP-2 and 
MMP-2 (Konttinen et al. 1998). It is produced by synovial fibroblasts but also by 
macrophages and osteoclasts. MMP-14 plays a role, not only in the fibroblast-mediated 
matrix degradation, but also in osteoclast-mediated bone resorption (Pap et al. 2000, Delaisse 
et al. 2003) and is the only MT-MMP expressed in chondrocytes. It can activate pro-MMP-2 
and pro-MMP-13, which points out, that fibroblasts, macrophages and chondrocytes may co-
operate in the degradation of cartilage and bone. In our analysis, mRNA expression levels of 
MMP-14 in OA and RA were very low (Figure 7B), but at a similar level (Figure 7A), 
suggesting perhaps a role in osteoclast and chondrocyte mediated rather than pannus driven 
cartilage tissue destruction. Miller et al. (2009) found high expression of MMP-14 at the 
cartilage-pannus junction in RA joints, which also points out the function of high and 
localized expression of factors at the exact site of degradation.  
 
MMP-1 (interstitial collagenase) was the first detected MMP in rheumatoid synovium 
(Evanson et al. 1967). Previous studies have shown an important role for MMP-1 in cartilage 
collagen II degradation (Saito et al. 1998), while MMP-3 (stromelysin-1) is capable to 
degrade another cartilage matrix component, namely proteoglycan (Sapolsky et al. 1976). In 
our preliminary data MMP-1 was expressed in all RA and a few trauma samples, while 
MMP-3 was constitutively expressed in both conditions, but much more so in RA (Table 3). 
Increased expressions of MMP-1 and MMP-3 have been reported in rheumatoid synovial 
membrane (Hasty et al. 1990, Sorsa et al. 1992), in synovial fluid (Yoshihara et al. 2000) and 
in synovial cells (Okada et al. 1987), which correlates with invasive properties (Tolboom et 
al. 2002). MMP-3 acts as an indicator of disease activity and of the development of 
radiological damage in RA (Posthumus et al. 2000) and studies of MMP-3 knockout mice 
suggest an important role for it as a pro-MMP activator and in tissue degradation (van Meurs 
et al. 1999). MMP-1 levels seem to correlate with the degree of synovial inflammation 
(Maeda et al. 1995). Inhibition of MMP-1 reduces the invasiveness of RA synovial 
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fibroblasts (Rutkauskaite et al. 2004). Our conventional PCR data showed both MMP-1 and 
MMP-3 to be intensively expressed in RA samples, but with quantitative PCR a clear 
difference was observed in their expression levels. Both MMPs were increased in pannus 
tissue compared to synovial tissues (Figure 7A), but MMP-3 was found in pannus tissue in 46 
times higher levels than MMP-1 (Figure 7B). In addition, MMP-1 had higher mRNA levels 
in OA than in RA synovium, while MMP-3 was particularly high in pannus tissue, which 
indicates an important role for MMP-3 in RA cartilage tissue destruction. MMP-1 and MMP-
3 were also studied at protein level, which showed a similar pattern so that MMP-1 staining 
was weaker than MMP-3, but both showed increased staining in pannus compared to 





Figure 8. Western blots showing latent 52 kD form of MMP-1, and latent 57 kD, intermediate 
53 kD and active 45 kD forms of MMP-3 (together with a 50 kD molecular weight standard). 
Samples represent osteoarthritic synovial tissue (ST/OA, n = 2), rheumatoid arthritic 
synovial tissue (ST/RA, n = 2) and pannus tissue (PT/RA, n = 2), two lanes each.  
 
MMP-1 and MMP-3, because two different antibodies were used and MMP-1 antibody might 
due to its inherent properties give weaker staining than MMP-3 antibody. However, 
expression of the active 45 kD form of MMP-3 was clearly seen in pannus tissue extracts but 
this form of MMP-3 was weak in synovial tissue and was not expressed in OA synovium at 
all, while no active 43 kD form of MMP-1 was seen in any of the samples studied. 
Involvement of MMP-1 and MMP-3 in pannus tissue invasion has been indirectly supported 
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by a study dealing with the metastasis-associated protein S100A4, which promotes 
remodelling of the extracellular matrix and thus promotes progression of cancer and tumor. It 
was shown to be expressed in RA and to upregulate both of these MMPs (Senolt et al. 2006). 
Extracellular matrix metalloproteinase inducing protein EMMPRIN is similarly increased in 
RA synovial membrane (Konttinen et al. 2000b). 
 
Based on these results and knowing that MMPs in general are upregulated by IL-1β and 
TNF-α, the effects of these cytokines on MMP-1 and MMP-3 in cultured synovial fibroblasts 
were studied. Our mRNA expression data indicate that TNF-α is more potent stimulator of 
MMP-1 and IL-1β of MMP-3 (Figure 9A), MMP-3 expression increasing 300-fold by it 
(Figure 9B). MMP-1 level has been shown to correlate with the degree of synovial 
inflammation (Maeda et al. 1995). In RA expression of TNF-α may precede that of IL-1β. 
This has been suggested by observations showing that IL-1β is particularly involved in 
advanced RA with progressive hard tissue degradation (Marinova et al. 1997, Abramson et 
al. 2002) and that in animal models of arthritis blocking of IL-1 reduces cartilage degradation 
and bone erosions, whereas blocking of TNF decreases synovitis (Strand and Kavanaugh, 
2004). This has also been explained by uncoupling of inflammation from cartilage and bone 
tissue degradation in RA indicating that although inflammation would be under control, hard 
tissue destruction may proceed at least in part via mechanisms separate from those causing 
synovial inflammation (Van den Berg 1998). MMP-1-mediated degradation of cartilage type 
II collagen may be mediated, not by pannus, but by chondrocytes of the cartilage. Earlier 
studies of IL-1-driven animal models showed rapid and extensive cartilage damage and it has 
also been reported that IL-1 leads to proteoglycan loss and matrix degradation (van den Berg 
et al. 2002, Pettipher et al. 1986). On the contrary, TNF seemed to be a less potent inducer of 
matrix degrading enzymes than IL-1 and in TNF-driven disease cartilage damage may be 
influenced by IL-1 acting downstream from it. The conclusion is that TNF-α stimulated 
MMP-1 expression is involved in inflammation during early RA and IL-1β stimulated MMP-
3 is involved in cartilage degradation in more advanced RA, when the cartilage degradation is 
driven by invasive pannus tissue. In a recent study TNF-mediated cartilage damage was 
indeed shown to be dependent on downstream located IL-1 and that IL-1 deficiency in mice 
decreased MMP-3 expression, suggesting that IL-1 and MMP-3 are the key factors in 
inflammatory cartilage tissue degradation (Zwerina et al. 2007). 
 





Figure 9. A) Quantitative mRNA expression levels of MMP-1 and MMP-3, normalized for 
porphobilinogen deaminase in non-stimulated fibroblast cultures (Ctrl, n = 3) compared to 
TNF-α or IL-1β stimulated fibroblast cultures (n = 3). B)  Quantitative mRNA expression 
levels of MMP-1 and MMP-3 normalized for porphobilinogen deaminase in non-stimulated 
(negative control, n = 3) and TNF-α and IL-1β stimulated (n = 3) fibroblast cell cultures 
shown in the same scale. 
 
IL-17 is one of the new potential cytokine targets in the management of RA. IL-17 expression 
has been shown to be increased in inflamed tissue (Beklen et al. 2007), but the expression 
levels were quite low, as also in our study in RA (Figure 10A). Expression levels of IL-17 
were slightly increased in pannus tissue (Figure 10A), but IL-17 did not have any major 
influence on MMP-3 expression (Figure 10B). Increased IL-17 levels have been observed 
during the early stages of the disease in synovial fluid and synovial tissue (Kotake et al. 1999, 
Chabaud et al. 1999), but a recent study showed that less than 1% of T cells in RA synovium 
are positive for IL17A. It therefore seems that IL-17 is not a good stimulator candidate of 
fibroblast MMP-3 compared to TNF-α and IL-1β, but it might be involved in stimulation of 
TNF-α and IL-1β production (Beklen et al. 2007), particularly during the early stages of the 
disease and thus promote subsequent tissue destruction in RA. It has been suggested that IL-
17 occupies a place at the top of the inflammatory cascade and stimulates other cells, such as 
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fibroblasts and macrophages, to increased production of proinflammatory cytokines. RA is 
not necessarily an IL-17-predominated disease, but it might be that IL-17 plays an important 
role in the early stages of RA (Raza et al. 2005). Because IL-17 and IL-17 receptor comprise 






Figure 10. A) Quantitative mRNA expression of IL-17 normalized for β-actin in 
osteoarthritic synovial tissue (ST/OA, n = 4), rheumatoid arthritic synovial tissue (ST/RA, n 
= 4) and pannus tissue (PT/RA, n = 4). B) Quantitative mRNA expression of IL-17 
normalized for β-actin in nonstimulated (ctrl, n = 2) and 10, 1 and 0.1 ng/ml TNF-α, IL-1β or 
IL-17 stimulated (n = 2) fibroblast cell cultures. 
 
7.2 Cartilage degradation by pannus-derived proteinases (I, II) 
 
In RA different proteinases can contribute to joint destruction by directly degrading the 
cartilage and to pannus invasion by degrading extracellular matrix and indirectly by 
activating other proteinases capable of doing so. Synovial fibroblast- and macrophage-like 
cells can release proteinases capable of digesting the cartilage matrix components and this 
destruction occurs primarily in areas close to inflamed pannus tissue in RA (Kobayashi and 
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Ziff 1975, Edwards 2000). The increased activity of proteolytic enzymes observed in arthritic 
joints may preceed the matrix degradation but may represent also a consequence of debris 
resulting from damaged cartilage and bone tissue. 
 
It has been speculated that multiple members of the ADAMTS family may be important in 
connective tissue homeostasis and pathology. ADAMTSs cleave cartilage aggrecan mainly at 
the aggrecanase site (Glu373-Ala374), but some also secondarily at the matrix 
metalloproteinase site (Asn341-Phe342) (Westling et al. 2002). One of the aims of our study 
was to detect the eventual role of ADAMTSs in cartilage degradation. Because of earlier 
studies of involvement of ADAMTSs in aggrecan degradation and carcinomas, we studied 
the mRNA expression of ADAMTS-1, -4, -5, -12, -13 and -19 in RA and OA synovium as 
well as in pannus tissue. None of these ADAMTSs were increased in pannus tissue (Figure 
11) and the expression levels were rather low compared to MMP levels (Figure 7B). Levels 
of ADAMTSs were normalized in these experiments for PBGD, because expression levels 
were almost undetectable when compared to β-actin. Later studies have shown an eventual 
involvement of ADAMTS-4 and -5 in arthritic diseases, but these ADAMTSs were isolated 
from cartilage (Nagase and Kashiwagi 2003) and have been implicated in aggrecan 
degradation (Malfait et al. 2002). Both ADAMTS-4 and -5 knockout mice were 
phenotypically normal and underwent normal development (Glasson et al. 2004, 2005; 
Stanton et al. 2005). In a model of inflammatory arthritis, only ADAMTS-5 knockout mice 
were protected against aggrecan loss, suggesting that ADAMTS-5 is responsible for the 
increased aggrecanase activity and cartilage pathology. However, in vitro studies using 
siRNA, neutralising antibodies and immunoprecipitation suggested a significant role also for 
ADAMTS-4 in aggrecan degradation (Fosang et al. 2008). The insignificant expression of 
ADAMTS in pannus tissue, but their increased expression in cartilage chondrocytes, 
implicates that they are derived from chondrocytes. These data suggest that rheumatoid 
cartilage destruction is partly mediated by pannus-derived MMP-3 and chondrocyte-derived 
ADAMTS-4 and -5. MMP-3 might precede ADAMTS-mediated degradation in early stages 
of RA, when pannus is starting to invade into cartilage and chondrocytes have not been 









Figure 11. Quantitative mRNA expressions of ADAMTS-1, -4, -5, -12, -13 and -19 
normalized for PBGD in osteoarthritic synovial tissue (ST/OA, n = 4), rheumatoid arthritic 
synovial tissue (ST/RA, n = 4) and pannus tissue (PT/RA, n = 4). 
 
MMP-3 is not able to cleave collagen type I and II, but it has been shown to be important in 
cartilage proteoglycan (aggrecan) degradation. As was discussed earlier, MMP-3 is not 
involved in early stage RA, but more in advanced stages when degradation of cartilage 
occurs. The pH optimum of MMPs is usually between 7.5 and 8.0, but MMP-3 has a pH 
optimum between 5.5 and 6.0 so it can digest its substrates both in acidic and neutral 
environments. This lower pH optimum might be an advantage in pannus-mediated tissue 
degradation, because the junction between the pannus and hard tissue may develop a low pH. 
Measurements on cartilage affected by osteoarthritis demonstrate an acidic pH between 5.5 
and 6.2 in this cartilage layer (Konttinen et al. 2002). Bone resorbing osteoclasts do not 
invade into non-mineralized cartilage but also these cells need an acidic pH for bone collagen 
degradation. Indeed, the acidic cysteine endoproteinase cathepsin K has been shown to be the 
key enzyme in osteoclastic bone resorption, but it may also play an important role in the 
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progressive destruction of articular cartilage, if the acid-base milieu enables activity 
(Konttinen et al. 2002). 
 
The apparently low pH in cartilage-pannus junction is thus permissive, not only for MMP-3 
activity, but also for cathepsin K and other cathepsins which are acidic endoproteinases. 
Inhibition of cathepsin L reduced cartilage destruction in a mouse arthritis model (Schedel et 
al. 2004) suggesting that these acidic enzymes are involved in the degradation of type II 
collagen. Cathepsins belong to the cysteine endoproteinase family. Their potential 
extracellular role is in the degradation of ECM proteins, such as fibronectin, laminin and 
collagen types I, II, IV, XVII, and bone matrix proteins, such as osteopontin, osteocalcin and 
osteonectin as well as  in the activation of proenzymes. Based on the capability of cathepsins 
to degrade collagen, we investigated the mRNA expression of cathepsins K, L and B in 
pannus tissue compared to RA and OA synovium. All these cathepsins have been previously 
found in synovium and at the soft-hard tissue junction in RA (Trabandt et al. 1990 and 1991, 
Hummel et al. 1998, Kaneko et al. 2001), but our results do not suggest that they play a role 
in pannus, because their expressions levels were highest in RA synovium and second highest 
in OA synovium being relatively low in pannus tissue (Figure 12A). Similarly, the expression 
levels were higher in primary cultures of RA synovial fibroblasts than in primary cultures of 
pannus fibroblasts. The most potent stimulator of cathepsin L and B in RA synovial 
fibroblasts in 48-hour experiments was IL-17, which had low expression in pannus tissue as 
shown previously, but which in in vitro experiments was even more potent stimulant than 
TNF-α and IL-1β (Figure 12B). Interestingly, cathepsin B was the predominant cathepsin in 
monocyte/macrophages, while cathepsin L was 10 times lower and cathepsin K was not 
detected at all. Previous data also shows cathepsin L and B expression in monocytes (Reddy 
et al. 1995) and that cathepsin B is capable to activate pro-MMP-3 (Murphy et al. 1992). 
Inhibition of cathepsin L protein synthesis in a mouse arthritis model reduced cartilage 
destruction (Schedel et al. 2004). However, all these cathepsins are also expressed in 
chondrocytes suggesting that they might play a role in chondrocyte-mediated cartilage 
remodelling and destruction (Lang et al. 2000, Konttinen et al. 2002). In contrast, it seems 
that cartilage degradation is not mediated by cathepsin derived from pannus itself. Cathepsins 
K, B and L have been shown to degrade type II collagen and proteoglycans so they can 
contribute to cartilage degradation (Maciewicz et al. 1990, Maciewicz and Wotton 1991, Hou 
et al. 2001). Another explanation for the role of cathepsins found in synovial fibroblasts 
could be their involvement in the degradation of endocytosed cartilage collagen (Hou et al. 
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2001) after other neutral endoproteinases, like MMPs, have first partly degraded cartilage 




Figure 12. A) Quantitative mRNA expressions of cathepsin K, L and B normalized for β-actin 
in osteoarthritic synovial tissue (ST/OA, n = 9), rheumatoid arthritic synovial tissue (ST/RA, 
n = 9) and pannus tissue (PT/RA, n = 8). B) Quantitative mRNA expression of cathepsin K, L 
and B normalized for β-actin in nonstimulated (ctrl, n = 2) and TNF-α, IL-1β or IL-17 
stimulated (n = 2) rheumatoid arthritic synovial fibroblasts (SF/RA), pannus fibroblasts 
(PF/RA) and monocytes from peripheral blood (MONO) at 48 hours. 
 
7.3 Osteoclast formation (IV) 
 
Multinuclear bone resorbing osteoclasts are formed by fusion of mononuclear progenitor 
cells. Before the fusion process cells are involved in a series of steps to achieve fusion 
competence. First some signal initiates differentiation leading to changes in cell phenotype 
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and shape. Before the final fusion steps the cells also have to recognize their fusion partner 
for proper adherence.  
 
The differentiation of mononuclear progenitors to fusion competence is stimulated by M-CSF 
via c-fms receptor and by RANKL via its receptor RANK expressed on these prefusion cells. 
In our studies both human peripheral blood mononuclear cells and mouse monocyte-
macrophage RAW 264.7 cells were used as the source of progenitor cells. We also explored 
if RANKL and its decoy receptor OPG are expressed in pannus tissue. Immunological 
staining of RANKL indicated that it is present in pannus tissue, often located close to 
multinuclear cells expressing TRAP used as an osteoclast marker. RANKL staining and the 
presence of multinucleated cells in areas where pannus invades into bone in RA has been 
indicated in other studies (Gravallese et al. 2000). We also detected increased RANKL 
mRNA expression in pannus tissue compared to RA and OA synovium, which is in line with 
the increased expression of corresponding protein in pannus. Messenger RNA expression of 
OPG was also detected, which would tilt the balance to the opposite direction. When RANKL 
was increased, its inhibitor factor OPG was decreased, which we conclude promotes 
osteoclastogenesis (Figure 13A). This has been confirmed also by other groups (Fonseca et 
al. 2005, Pettit et al. 2006). In normal knee joints, excessive expression of OPG over 
RANKL has been measured, suggesting the role of OPG in protection against joint damage 
(Smith et al. 2003). However, much of OPG may be localized in the vascular endothelial 
cells (Mandelin et al. 2003b) and may there participate in the interactions between 
endothelial RANK and vascular smooth muscle cells and mast RANKL rather than 
osteoclastogenesis (Ali et al. 2006). Next we wanted to study RANKL expression in pannus 
fibroblasts and to study the effect of different stimulators on RANKL expression. RANKL 
expression levels were higher in pannus fibroblasts than in RA synovial fibroblast (Figure 
13B) and all the stimulants used, TNF-α, IL-1α and IL-17, increased RANKL expression in 
fibroblasts (Figure 13C), TNF-α being the most effective stimulant, which has been recently 
also observed by another group (Tunyogi-Csapo et al. 2008).  
 
 





Figure 13. A) Quantitative mRNA expressions of RANKL and OPG, normalized for β-actin in 
osteoarthritic synovial tissue (ST/OA, n = 9), rheumatoid arthritic synovial tissue (ST/RA, n 
= 9) and pannus tissue (PT/RA, n = 8). B) Quantitative mRNA expressions of RANKL 
normalized for β-actin in rheumatoid arthritic synovial fibroblasts (SF/RA, n = 3) and 
pannus fibroblasts (PF/RA, n = 3). C) Quantitative mRNA expressions of RANKL, 
normalized for β-actin in nonstimulated fibroblasts (ctrl, n = 2) and fibroblasts stimulated 
with 10, 1 and 0.1 ng/ml TNF-α, IL-1β and IL-17 (n = 2). 
 
It is known that the essential signalling pathway for osteoclastogenesis involves NF-kappa B. 
RANKL binding to RANK on the surface of osteoclast precursors leads to NF-kappa B 
activation, via tumor necrosis factor receptor-associated factors (TRAFs) and translocation to 
the nucleus to activate the transcription factors for osteoclastogenic gene expression. TNF-α 
can also induce NF-kappa B signalling by direct binding to its own receptor (Li et al. 2008). 
Stimulation of cells with TNF-α triggers activation of NF-kappa B through various signalling 
molecules, which include TRAF. The negative regulation of NF-kappa B signalling is 
essential for the normal function of cells and failure to down-regulate the NF-kappa B-
mediated signalling may lead to chronic inflammation and this might be the main effect of 
increased TNF-α levels in RA, as earlier stated. Osteoclastogenesis can be triggered by IL-17 
through the up-regulation of RANKL on fibroblasts and other cells through IL-17 receptor 
induced NF-kappa B activation (Sato et al. 2006, Kotake et al. 1999). Deficiency of IL-17 
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alone did not reduce inflammatory bone destruction (Tunyogi-Csapo et al. 2008), but IL-17 is 
not only capable to induce RANKL production, but it can also induce proteinases and can 
that way contribute to cartilage and bone degradation. 
 
To confirm fibroblast function in osteoclast formation, we co-cultured osteoclast precursor 
cells with pannus fibroblasts with M-CSF but without RANKL to follow the eventual 
formation of multinuclear TRAP+ osteoclast-like cell. This interaction might be the result of 
cell-cell contact mediated via RANKL/RANK interaction or via soluble RANKL produced 
by fibroblasts. It has been earlier reported that RA synovial fibroblasts express higher than 
normal levels of RANKL and seem therefore to induce osteoclast-like cells more effectively 
than synovial cells expressing only low levels of RANKL (Shigeyama et al. 2000). We also 
checked if TNF-α, IL-1β and IL-17 stimulated monocyte/macrophages express RANKL, but 
none was observed although it has been shown that numerous cell types in tissue of collagen-
induced arthritis in mice, including macrophages and fibroblasts, are capable to produce 
RANKL (van den Berg et al. 2007). This difference might be due to distinct activation routes 
in cytokine stimulated cultured cells and in collagen induced arthritis. Inhibition of RANKL 
by its natural inhibitor OPG in mouse models confirms the role of this factor in 
osteoclastogenesis by preventing peri-implant osteolysis (Goater et al. 2002) and formation 
of erosions in RA (Kong et al. 1999). 
 
After initial differentiation the mononuclear precursor cells should come into direct cell-cell 
contact with other fusion competent cells. It has been suggested that some members of the 
ADAM family contain a putative fusion peptide responsible for promotion of cell fusion 
upon cell-cell contact. Because it had already been reported that ADAM8, 9 and 12 seem to 
be involved in the formation of multinuclear osteoclasts (Yagami-Hiromasa et al. 1995, 
Namba et al. 2001, Choi et al. 2001), we wanted to investigate first the mRNA expression of 
these ADAMs in the bone-pannus junction. Only ADAM8 showed a clearly increased 
expression in pannus tissue compared to RA and OA synovial tissues and ADAM9 was even 
more highly expressed in OA synovial samples (Figure 14A). As mentioned, it had been 
earlier suggested that ADAM8 is involved in osteoclast formation and that its inhibition in 
mouse bone marrow culture decreases osteoclast formation (Choi et al. 2001) and its role in 
cell fusion is also supported by a recently published study from our group (Ma et al. 2009). 
Therefore, we focused our studies to ADAM8 and next observed that, apart of its already 
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mentioned increased mRNA expression (Figure 14B), also the corresponding protein was 




Figure 14. A) Quantitative mRNA expressions of ADAM8, -9 and -12 normalized for β-actin 
in osteoarthritic synovial tissue (ST/OA), rheumatoid arthritic synovial tissue (ST/RA) and 
pannus tissue (PT/RA). B) In situ hybridization of ADAM8 mRNA at pannus-hard tissue 
junction. C) Immunohistochemical staining of ADAM8 protein at the cartilage/bone-pannus 
junction. Scale bar 50 μm. HT, hard tissue. 
 
multinuclear osteoclasts, ADAM8 expression was increased (Figure 15A and B), however in 
multinuclear cells, the expression started to diminish (Figure 15A, days 7 and 9), indicating 
that it is functioning in forming osteoclasts. ADAM8 function was studied in mouse 
macrophage RAW cells by silencing ADAM8 expression with small interfering RNA 
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(siRNA) duplex oligos and by increasing its expression using transfection with a cloned full-
length ADAM8 vector. The eventual effect of both procedures on osteoclast formation was 
assessed by measuring mRNA expression of several osteoclast markers, namely TRAP, 
calcitonin receptor, integrin β3 and cathepsin K. These markers were decreased and increased 
during stimulated osteoclastogenesis upon silencing and transfection of ADAM8, 




Figure 15. A) Immunohistochemical staining of ADAM8 (red colour) protein on RANKL 
stimulated RAW 264.7 macrophage cell cultures during their differentiation into osteoclast-
like multinuclear cells at 1, 3, 5, 7 and 9 days. Nuclei are visualized by DAPI staining (blue 
colour). Scale bar 100 μm. B) Quantitative mRNA expression of ADAM8 normalized for β-
actin in non-treated controls (-) and RANKL stimulated (+) RAW 264.7 macrophage cell 
cultures during their differentiation into osteoclast-like multinuclear cells. The duration of 
stimulation is indicated in days (n = 3). 
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cells. The effects of cytokines on ADAM8 mRNA and protein expression during 
osteoclastogenesis, detected using quantitative PCR and flow cytometry, pointed out that at 
least IL-1β and M-CSF play a role for ADAM8 expression. The modular ADAM8 protein is 
a transmembrane protein, which contains a pro-domain followed by a metalloproteinase 
domain and is further in the C-terminal direction flanked by potential adhesion and fusion 
active disintegrin and cysteine-rich domains. These are further followed by a transmemrane 
domain and an intracellular domain. Catalytic metalloproteinase activity of ADAM8 
resembles that of the MMPs, such as MMP-2, MMP-3 and MMP-13 (Yamamoto et al. 1999, 
Amour et al. 2002) and the substrate specificity at least for proteoglycans occurs also in low 
pH optimum, which might favour the tissue degradation in junction between the acidic 
pannus and hard tissue (Hall et al. 2009b). For the release of the active site of the 
metalloproteinase domain the blocking pro-peptide domain has first to be cleaved off and, 
similarly, for the release of the fusion active domain, the metalloproteinase domain should be 
removed (Figure 16A). We studied this aspect with Western blotting using an antibody 
against the intracellular domain of the ADAM8 protein. Indeed, we noticed that before (and 
during) the formation of multinuclear osteoclasts the pro-domain was first cleaved off and 
this was followed by removal of the metalloproteinase domain as if to release the activity of 
the putative fusion active domain (Figure 16B). Based on studies utilizing deleted forms of 
ADAM8 it has been concluded that the direct cell-to-cell contact is mediated via its 
disintegrin/cysteine-rich domains (Choi et al. 2001). Not only the cysteine-rich domain, but 
also the epidermal growth factor-like domain, found in some other ADAM family members, 
are both homologous to viral fusion proteins and are involved in membrane fusion (Huovila 
et al. 1996). Interactions between the disintegrin domain of ADAM8 and integrin receptors 
on osteoclast precursor cells may be the event triggering cell membrane and cellular fusion. 
The disintegrin domain of ADAM8 does not contain RGD sequences, but it can interact with 
alpha9-beta1 integrin, which is expressed on osteoclast precursors and which increases during 
their differentiation to osteoclasts (Rao et al. 2006). However, it has been reported that the 
soluble form of ADAM8 can also induce cell fusion and it can therefore be concluded that the 
cell-to-cell contact is not the only way ADAM8 may potentially support formation of 
multinuclear cells. Increased expression of ADAM8 has also been found in synovial fluid of 
RA patient and its concentrations correlate with the degree of joint inflammation (Gomez-
Gaviro et al. 2007). These data make ADAM8 a potential therapeutic candidate molecule, 
which could first mediate cartilage matrix destruction due to its proteolytic properties and 
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subsequently increase bone degradation due to its potential role in osteoclastogenesis during 




Figure 16. A) On the left the proteolytically active ADAM8 mediates degradation of cartilage 
after cleavage of the pro-domain exposing the metalloproteinase domain (MP). Upon further 
removal of the metalloproteinase domain the fusion active disintegrin domain (DI) able to 
mediate osteoclastogenesis is released, which leads to the formation of osteoclasts and 
osteolysis. B) Conversion of ADAM8 pro-form (120 kD) into proteolytically active 
metalloproteinase (75 kD) and further to fusion-active disintegrin (55 kD) in RANKL 
stimulated (+) RAW 264.7 macrophage cultures at 7 and 9 days assessed using Western blots 
compared to non-stimulated (-) RAW cells. 
  
7.4 Bone degradation (V) 
 
Our previous data showed only minor expression of cathepsin K in pannus tissue, which 
might indicate that only a few osteoclasts are involved in the formation of erosions, but which 
also made it necessary to study this in more detail. To do this a pycnodysostosis patient with 
bone erosions was analyzed. Her peripheral blood monocytes were studied for their ability to 
mediate cathepsin K-independent bone resorption.  
 
Osteoclasts are responsible for bone resorption and bone degradation is thus regulated by 
their number and activity level. Multinuclear cells, with osteoclastic phenotype expressing 
calcitonin receptor, cathepsin K and TRAP, are found in pannus tissue adjacent to bone 
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(Bromley and Woolley 1984, Gravallese et al. 1998, Goldring and Gravallese 2000). 
Synovial fibroblasts and T-cells are considered to be the primary source of osteoclastic 
factors in synovial membrane. Mature osteoclasts, together with activated macrophages, 
mediate bone destruction by secreting proteinases, including MMPs and cathepsins, which 
degrade demineralised bone matrix. Cathepsin K is known to be a one of the most important 
proteinases involved in osteoclast-mediated bone loss and cathepsin K has been used as an 
osteoclastic marker to verify formation of multinuclear osteoclastic cells. Cathepsin K mRNA 
expression increases during osteoclastogenesis. In RA cathepsin K-positive cells have been 
observed in hypertrophic synovitis tissue and at sites of cartilage and bone degradation 
(Hummel et al. 1998, Gravallese et al. 2000, Hou et al. 2001). Cathepsin K is also found in 
synovial fibroblasts and its expression is increased in RA synovitis tissue compared to control 
synovial tissue (Hou et al. 2001). Serum cathepsin K levels correlate with radiological 
progression of bone destruction (Skoumal et al. 2005). Cathepsin K has also been reported to 
be present in macrophages in RA (Hou et al. 2001). Noteworthy, our experiments showed no 
cathepsin K mRNA expression in unstimulated healthy monocyte/macrophages or TNF-α, 
IL-1β and IL-17 stimulated monocyte/macrophages at 48 hours. In our study we analyzed 
cathepsin K mRNA expression and it was not increased in pannus tissue or in pannus-derived 
fibroblasts compared to RA and OA synovial tissue (Figure 12A) or synovial fibroblasts 
derived from such tissues (Figure 12B). Synovial fibroblasts can internalize collagen type II 
and accumulate it within their lysosomes, suggesting the cathepsin K postitive fibroblasts 
might play a role in the clearance of endocytosed collagen at the site of cartilage erosion 
(Hou et al. 2001) and a similar process could happen in the bone-pannus junction also for 
collagen type I.  
 
In human osteoclasts, that express little or no cathepsin B and L, it is supposed that cathepsin 
K mediates degradation of collagen type I and other bone-matrix-associated proteins like 
osteopontin, osteocalcin and osteonectin. If cathepsin K production or activity is inhibited, 
osteoclasts most probably are not able to mediate bone collagen matrix degradation. This is 
why the involvement of cathepsin K in bone degradation was studied more closely by using 
peripheral blood mononuclear cells from our pycnodysostosis patient. Pycnodysostosis is 
characterized by cathepsin K deficiency and due to the lack of cathepsin K osteoclasts of 
pycnodysostosis patients can not maintain normal bone remodelling leading to impaired 
development of the skeleton (short stature), ineffective bone resorption and abnormally dense 
bones (osteosclerosis). However, in spite of this it became evident that our pycnodysostosis 
 Results and discussion  
71 
 
patient, who by accident had also developed an inflammatory arthritis, developed bone 
erosions (Figure 17). This “Experiment of Nature” represents a “human cathepsin K knock-
out” arthritis model. Interestingly, a recent study indicates that cathepsin K knock out does 




Figure 17. Bone erosions and acro-osteolysis in toes of the pycnodysostosis patient suffering 
from psoriatic arthritis. X-ray of normal toes (A) and of a pycnodysostosis patient from year 
2005 (B). Panel B demonstrates patient’s foot with erosive changes in II and V MTP joints 
(a), complete resorption of the distal phalanges of digits III-IV (b) and partial resorption of 
the mid phalanges of digits III and IV (c). Also malunion after an attempted arthrodesis of the 
I MTP joint can be seen. 
 
(Schurigt et al. 2008). Serum of our pycnodysostotic arthritis patient was analysed for 
collagen degradation products generated by cathepsin K (CTx for cross-linked collagen 
telopeptides produced from mature collagen fibers by the action of cathepsin K) and for 
collagen degradation products generated from mature collagen fibers by collagenolytic 
MMPs (ICTP for type I collagen telopeptides). The results showed only very low CTx values, 
within the limits of the method background values, but high ICTP values further verifying 
cathepsin K deficiency. Mononuclear cells were differentiated into multinuclear osteoclasts, 
which were analyzed for cathepsin K, TRAP and calcitonin receptor as osteoclast markers. 
These results indicate that TRAP and calcitonin receptor expression were similar to those of 
the healthy controls, but as supposed, cathepsin K was missing in patient samples. Formation 
of multinuclear TRAP positive osteoclast-like cells was similar in our pycnodysostosis 
patient and our healthy control on both culture plates and on dentine discs (Figure 18A and 
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B). Thus, lack of cathepsin K did not seem to much affect the formation or the number of 
multinuclear cells. However, the analysis of the capability of the osteoclast-like cells to erode 
bone discs showed that the resorption pits formed different patterns. Osteoclasts from the 
healthy control formed normal resorption pits with trails (Figure 18D), but the osteoclasts 
from our pycnodysostosis patient formed resorption pits without trails as if they had lost their 
ability to migrate on the surface of the dentine slice (Figure 18E). This must be somehow 
connected to the loss of cathepsin K. Therefore, it was next tested how inhibition of cathepsin 
K activity in healthy control osteoclasts affects formation of resorption pits. The results of 
these experiments further suggest that cathepsin K participates in osteoclast migration, 
because formation of multinuclear cells was not affected (Figure 18C). Furthermore cathepsin 
K-inhibited osteoclasts showed the same pattern as osteoclasts generated from the osteoclast 
precursors of the pycnodysostosis patient, being apparently rather sessile on dentine slices 




Figure 18. Bone resorption by M-CSF and RANKL induced human osteoclasts. 
Immunohistochemical staining of the osteoclast marker TRAP in multinuclear cells from (A) 
a normal control, (B) pynodysostosis patient and (C) in cathepsin inhibited multinuclear cells 
from a normal control cultured on dentine discs. Toluidine blue staining of resorption pits 
formed by the corresponding (D) normal control cells, (E) pynodysostosis cells and (F) 
cathepsin inhibited normal control cells on dentine discs.  
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several molecules, it is concluded that cathepsin K, although necessary for osteoclast 
migration, is probably not the only relevant factor in it. 
 
Cathepsin K activity and collagen degradation products CTx and ICTP were measured over 
time in cell culture supernatants from dentine disc, which contained osteoclasts produced 
from cells of the healthy control or the pycnodysostosis patient. As supposed, active 
cathepsin K levels of the pycnodysostosis osteoclast cultures were under detection level. This 
was accompanied by lack of CTx type collagen degradation products, whereas the ICTP 
levels in the culture supernatants were higher than in the control samples. This might be due 
to a compensatory and increased MMP-mediated degradation of bone and/or missing of the 
second cathepsin K-mediated degradation step of ICTP to CTx, which however both 
represent a consequence of the cathepsin K deficiency. In line with this reasoning, a recent 
study suggests that the loss of cathepsin K can be compensated in addition to other MMPs 
and cysteine proteinases (Everts et al. 2006), also by some still unknown proteinases. This 
study may also suggest that different sites of bone contain different osteoclasts, which could 
use different sets of proteinases for bone matrix degradation. Chondroclasts could belong to 
one of these types, which are shown to degrade mineralized cartilage and which resamble 
osteoclastic cells (Schenk et al. 1967). Osteoclast is the primary bone resorbing cell, but on 
the other hand, synovium-derived proteases may participate directly in the degradation of 
cartilage and bone in RA (Jones et al. 2008). Also fibroblast-like cells may be involved in 
bone resorption (Pap et al. 2003). Fibroblasts were shown to release acidic molecules to 
lower the pH in their immediate surrounding, which could lead to acidification of the 
microenvironment between the pannus and cartilage/bone, demineralization of the calcified 
bone matrix and activation of the acidic MMP-3 and cathepsin K during pannus invasion. 
Breast cancer cells can participate in degradation of organic bone matrix (Parikka et al. 
2005), which also support the involvement of invasive synovial fibroblast-like cells in 
cartilage/bone degradation. Based on these results, it is concluded that although cathepsin K 
plays a pivotal role in the progressive destruction of bone matrix, it is not solely responsible 





8. SUMMARY AND CONCLUSIONS 
 
Summary I: Matrix metalloproteinases are involved in extracellular matrix degradation and 
analysis of 16 different MMPs in RA synovium revealed the presence in particular and 
eventual role of MMP-1, MMP-3, MMP-13 and MMP-14 in the development of RA when 
compared to the synovial tissue samples obtained from trauma patients. 
 
Summary II: More detailed analysis of MMP-1, MMP-3, MMP-13 and MMP-14 indicated 
that among these MMPs the most likely enzymes involved in pannus tissue mediated matrix 
degradation are MMP-1 and MMP-3. Both were increased in pannus, but MMP-3 was the 
predominant one. Stimulation studies suggest TNF-α as a potent stimulator for MMP-1 and 
IL-1β for MMP-3. Based on the present results and some recent findings, it is concluded that 
MMP-1 is involved in inflammation and pannus tissue expansion during early RA, while 
involvement of MMP-3 in cartilage degradation becomes more prominent in advanced RA. 
In bone degradation also the eventual role of osteoblast produced MMPs, like MMP-13 and 
MMP-14, should be taken under consideration in RA. It can also be concluded that various 
stimulators and effectors are involved in the progression of RA during different stages. The 
eventual presence and participation of ADAMTSs in cartilage degradation was also studied, 
but these analyses suggest that they do not have any major involvement in pannus-mediated 
cartilage remodelling and degradation. 
 
Summary III: Osteoclastic differentiation factor RANKL was characterized in pannus tissue 
and its expression was found to be increased in pannus compared to synovial tissues of RA 
and OA, while the expression of its natural inhibitor osteoprotegerin (OPG) was diminished 
in pannus tissue, indicating that the increased RANKL/OPG ratio may drive formation of 
multinuclear osteoclasts in pannus tissue. Indeed, immunopathological studies disclosed 
multinuclear osteoclast-like cells in the advancing edge of the pannus tissue close to bone 
matrix and in close contact to RANKL positive cells. These data indicate that during 
advancing pannus tissue invasion into bone matrix, the bone degrading osteoclasts are locally 
formed in pannus.  
 
Summary IV: This study suggests a role for ADAM8 in cell fusion during the formation of 
multinuclear osteoclast-like cells. ADAM8 expression was increased locally in pannus tissue. 
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These observations support the conclusion of the previous study suggesting local 
osteoclastogenesis in pannus tissue and their role in the formation of rheumatoid erosions. 
 
Summary V: Cathepsin K has been shown to be a key enzyme in normal osteoclastic bone 
resorption and it has probably an important role in the progressive destruction of articular 
cartilage in RA. However, it was found that the invading soft pannus tissue contains less 
cathepsin K than control synovial tissue although cathepsin K may be specifically located in 
and under pannus osteoclasts. It was shown that a pycnodysostosis patient, who also had 
arthritis, developed bone erosions in spite of her cathepsin K deficiency. These observations 
led to the hypothesis that apart from cathepsin K also other proteinases are involved in 





Figure 19. Schematic picture summarizing the proposed roles of factors presented in this 
work in pannus derived cartilage and bone degradation in RA. 
 
 Several proteinases have been found and each of them most probably has a specific role in 
normal homeostasis and in various destructive diseases. On the other hand, there is also 
redundancy and overlap between them. This study emphasized the latter aspect because 
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several proteinases were found in pannus tissue although some of them seem to be more 
important than others. Cartilage and bone destruction in RA seems to result form invasion by 
pannus and to be directly mediated by proteinases produced by cells in pannus. The 
capability of rheumatoid fibroblasts to produce cartilage and bone degrading enzymes, as 
well as to stimulate osteoclast formation, suggests that fibroblast may be an important cell in 
pannus invasion and in hard tissue destruction. Therefore, another task in RA research is to 
characterize further the phenotype of these fibroblasts and to find the triggering effects that 
initially induce the aggressive behaviour of these cells. 
 
The activity of proteolytic enzymes in the tissues is controlled at several steps, which include 
gene expression, protein production and secretion, activation of proenzymes and stabilization 
and/or inhibition of enzymes activities by natural inhibitors, e.g. TIMPs inhibiting MMPs; 
also inhibition of RANKL by OPG plays an important role. These molecules, especially 
various MMPs, have been intensively studied and many of them have been suggested to be 
involved in RA tissue destruction. For the past several years, both naturally occurring and 
synthetic inhibitors for MMPs have been studied as potential future therapeutic drugs, but 
many of these have failed in clinical trial for dose limiting toxicity and other adverse effects, 
and no compounds have been licensed for clinical use thus far. It has also become evident 
that some MMPs may actually exert anti-inflammatory effects. To overcome these 
challenges, it is necessary to understand the specific roles of various proteinases in more 
detail and then to design more selective inhibitors to target individual MMPs, perhaps for 
example MMP-3. However, the present work also suggests that inhibition of one single target 
may not be enough and that this target might be a moving target and differs during different 
stages of arthritis. Locally produced disease markers, like MMPs, could also be developed to 
prognostic indicators of severity of the erosive process as well as to demonstrate the degree 
of inflammation and the stage of inflammatory destruction in joints stricken with RA.  
 
None of the disease-modifying anti-rheumatic drugs (DMARDs) or biological agents or 
combinations thereof seems to be able to provide hundred percent long-term protections 
against joint destruction. TNF is a key regulatory cytokine in RA inflammation and has been 
shown to be a good therapeutic target. Accordingly, TNF blockers are the most widely used 
biologicals at present. Three anti-TNF biologicals have been registered in Finland. In 
combination with methotrexate (MTX) they diminish cartilage damage and bone destruction, 
probably in part by increasing OPG and thus reducing the effect of RANKL (Feldmann and 
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Maini 2008). However, serious adverse effects have been observed and some patients are 
non-responders or do not respond adequately. The trial and error approach, however, shows 
in retrospect that in most patients the benefits of anti-TNF treatment exceed the risks. 
Blockade of IL-1 has also been proved to be clinically beneficial (Konttinen L et al. 2006), 
but less so than TNF inhibitors, perhaps due to other cytokines, e.g. IL-17, overtaking the role 
of IL-1 (van den Berg et al. 2007). However, the combination of TNF and IL-1 completely 
blocked formation of bone erosion in a mouse model of arthritis, being more effective than 
monotherapies with one of these drugs alone (Zwerina et al. 2004). Blockade of IL-6 is a new 
therapeutic target in RA (Oldfield et al. 2009) and clinical trials with antibodies against other 
pro-inflammatory cytokines eg. IL-15 and IL-17 are in progress. Consideration, however, 
must also be paid to redundancy, because some cytokines have almost identical properties 
and the diversity makes it difficult to predict the additional value of the specific blockade of 
these cytokines.  
 
The use of gene therapy, stem cells and tissue engineering, has opened up new possibilities in 
treating arthritic diseases. One promising strategy is the antisense therapy, such as ribozymes, 
oligodeoxynucleotides (ODNs) and small interfering RNA (siRNA), which has a unique 
ability to down-regulate or silence gene expression by turning down the production of 
pathogenic proteins and cytokines. Some promising results have been observed in animal 
studies by inhibition of NF-kappa B, cathepsin or MMP expression to reduce pathological 
signs in arthritic joints and a few ribozymes have qualified for clinical trials. Recently, 
endogeneous microRNAs (miRNAs) have been in focus as a therapeutic target because of 
their ability to regulate various physiological and pathological processes. Few pilot trials 
using miRNA treatment have already been reported, but it is very likely that more epigenetic 
research based on miRNA will emerge in the near future. Mesenchymal stem cells are also 
known as bone marrow stem cells and multipotent mesenchymal stromal cells (adult stem 
cells) isolated from adult tissues. They have the potential to differentiate into various cells, 
including chondrocytes, osteoblasts and adipocytes, in response to appropriate stimuli and 
could be used for cell therapy in arthritic diseases. The usage of autologous stem cells from a 
patient, which are given back to that same patient, avoids the host rejection responses. A very 
important feature of stem cells, especially in treatment of RA, is their potent 
immunosuppressive and anti-inflammatory effects. Direct injection of stem cells into 
damaged tissue has been shown to decrease cartilage destruction and some clinical trials are 
going on. In tissue engineering stem cells are used to build a functional 3D scaffold to replace 
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damages tissue, especially cartilage with poor inherent repair properties. Marrow stimulation 
techniques, where holes were drilled into subchondral bone, and autografts, where healthy 
cartilage replaces the damaged tissue, are used, but also the autologous chondrocyte 
implantation (ACI) method and later matrix-induced ACI have been introduced. Nowadays 
much attention is paid to use of autologous stem cells in different kind of biodegradable 
scaffolds. 
 
The role of cathepsin K and RANKL in different bone diseases has inspired drug companies 
to produce specific inhibitors for the treatment of bone resorption and some of these 
pharmacological drugs have reached clinical trials. Various DMARDs and biologicals used in 
the treatment of RA, like methotrexate, sulfasalazine and infliximab, inhibit the expression of 
RANKL and increase the synthesis of OPG, a RANKL antagonist, in rheumatoid synovial 
fibroblasts (Lee et al. 2004). A promising tool for inhibition of erosive joint damage that 
results from osteoclast-mediated bone resorption is biological anti-RANKL antibody 
treatment, which has been shown in preliminary studies to decrease bone turnover and inhibit 
structural damage in patients with RA (Bekker et al. 2004, Cohen et al. 2008). Several 
studies have also demonstrated that OPG is a potent inhibitor of bone loss, which affects bone 
density and mass in mouse and humans (Bekker et al. 2001). Cathepsin K inhibitors have 
also successfully moved into clinical stages and have been found to inhibit collagen 
breakdown and to improve bone formation. The chemical structures of these selective 
inhibitors have not been revealed, but the available clinical data is encouraging and suggests 
that these inhibitors have potential to become novel disease-modifying drugs (Yasuda et al. 
2005). Transgenic mice expressing catalytically inactive ADAM8 expressed decrease 
incidence and severity of inflammatory arthritis whithout the risk of immunocompromise 
(Zack et al. 2009). ADAM8 is quite a novel protein in osteoclast research area and the 
research for its role in different diseases is ongoing and this molecule serves attention also as 
a diagnostic and prognostic marker and as a potential target for treatment. 
 
The articular protein network is very complex, especially from the point of view of selection 
of potential therapeutic targets. It has to be taken into consideration that expression patterns 
may differ between individuals and different disease stages and that parallel pathways exist 
so that the function of one can be overtaken by another. In principle, long-term administration 
may induce tolerance and reduce the efficacy, which may enforce to dose escalation, which 
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again may increase adverse effects. First and foremost, current drug therapies can provide 
remission and should be given early during the course of the disease, but they do not cure. 
Therefore, development of novel anti-RA drugs is still needed. RA is a very complex 
syndrome and it seems that it is difficult to induce remission by only one drug. Thus, instead 
of monotherapies, combination treatments are widely applied already using conventional 
anti-rheumatic drugs (Nordström et al. 2006). This may well apply also for current and future 
biological drugs, although at present the experiences of the use of biological drugs in 
combinations are not encouraging. Finally, it remains to be seen whether the drug 
combinations to be used should be tailored according to the stage of RA, e.g. in early vs. in 
advanced disease. The final goal is not only to alleviate symptoms but to prevent tissue 
damage, preserve function, induce clinical remission and – ultimately - to cure the patient.  
 
The initiating and perpetuating antigens or agents of chronic inflammation are not known, 
therefore, no treatment specifically targeting them exist. It seems that anti-inflammatory 
treatment alone with NSAIDs, coxibs, glucocorticoids, DMARDs or biologicals is not 
sufficient and that is why more attention should be paid to the cause and mechanisms of the 
disease initiating it and finally leading to cartilage and bone destruction. Usually when RA is 
diagnosed, the underlying disease has already been ongoing for a while and cartilage damage 
may already have developed. If it would be possible to make the diagnosis, when only 
aggrecan has been partially degraded but the supporting collagen network is still intact, the 
normal state of the cartilage could still be restored. In any case, understanding of the 
mechanisms responsible for cartilage and bone destruction and pannus invasion may open 
still new modes of prevention and treatment of this destructive joint disease and diminish the 
need for endoprosthetic surgery. 
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